MOLECULAR CHARACTERISATION AND PROPHYLACTIC TREATMENT STRATEGIES AMONG WOMEN WITH BENIGN GYNECOLOGICAL DISORDERS

Sakthivignesh Ponandai Srinivasan

Stockholm 2019
All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by E-Print AB 2019 © Sakthivignesh Ponandai Srinivasan, 2019 ISBN 978-91-7831-480-5

Cover page: Illustration of human uterus indicating the gynaecological disorders addressed in this thesis. Picture was coloured by Dhriti.V and Drish.V, 3.5 years old twins.
Molecular characterization and prophylactic treatment strategies among women with benign gynaecological disorders

THESIS FOR DOCTORAL DEGREE (Ph.D.)

To be publicly defended at J3:11 Birger & Margareta Blombäck, Bioclinicum, Solna.

Wednesday, 12th of June, 2019 at 9:00

By

Sakthivignesh Ponandai Srinivasan

Principal Supervisor:
Kristina Gemzell-Danielsson, Professor
Karolinska Institutet
Department of Women's and Children's health
Division of Obstetrics and Gynecology

Opponent:
Terhi T Piltonen, Professor
University of Oulu
Department of Obstetrics and Gynecology

Co-supervisor(s):
Monica Nister, Professor
Karolinska Institutet
Department of Oncology-Pathology
Division of Pathology

PGL Lalitkumar, Senior Researcher
Karolinska Institutet
Department of Women's and Children's health
Division of Obstetrics and Gynecology

Examination Board:
Matts Olovsson, Professor
Uppsala University
Department of Women's and Children's health
Division of Obstetrics and Gynecology

Cecilia Götherström, Docent
Karolinska Institutet
Department of Clinical science, intervention and technology
Division of Obstetrics and Gynecology

Jan-Bernd Stukenborg, Docent
Karolinska Institutet
Department of Women's and Children's health
Childhood Cancer Research Unit.
“The art of clinical diagnosis lies in the ability to ask the right questions.” -Harriet B. Braiker

Dedicated to wonderful ladies in my life
ABSTRACT

**Background:** Female reproduction is controlled by hormones in a timed and well-coordinated manner by the hypothalamus-pituitary-ovarian axis. In response to the ovarian hormones such as estrogen, and progesterone, endometrium, the inner lining of the uterus, undergoes repeated cycles of tissue growth, differentiation, tissue shedding and remodelling. However, dysregulation of those hormones, may generally cause uncontrolled cell proliferation, alteration of its invasive, migratory or angiogenic characteristics, leading to the displacement of endometrial tissues either outside of uterine cavity, for instance on ovary forming ovarian endometriosis; or inwardly into the myometrium causing adenomyosis. Several epidemiological studies as well as histological evidences have shown an increased risk of developing ovarian cancer among women with endometriosis known as endometriosis associated ovarian cancers (EAOC). Similarly, the risk of ovarian cancer is increased among carriers of *BRCA1* or *BRCA2* germline mutations due to error-prone DNA repair mechanisms.

**Aim:** We aimed to investigate on early molecular alterations associated with cancer development among women with ovarian endometriosis. In addition, treatment or preventive strategies for reducing disease symptoms were explored among women with ovarian endometriosis, *BRCA1* or *BRCA2* mutations and adenomyosis, respectively.

**Methods and Results:** Study I, we explored if there was a molecular link between endometriosis and ovarian cancer development, by analysing multipotent stem/stromal cells and tissues of endometrium and endometrioma among women with ovarian endometriosis. We investigated for intra-patient heterogeneity within stem- and cancer- cell- pathways using targeted PCR array as well as validated for their tumour initiating characteristics. We observed that a subgroup of women with endometriosis (4/30 endometrioma) exhibited dysregulation in estrogen receptor expression, upregulation of molecules related to epithelial-mesenchymal transition pathway such as *KIT*, *HIF2a* and *E-cadherin* as well as downregulation of tumour suppressor genes *PTEN* and *ARID1A*, thus supporting a link between above molecular changes and potential risk of EAOC.

Study II, we investigated the molecular regulation of Syndecan-1 (SDC-1) and -4 (SDC-4) upon induced activation of TGF-β signalling in another cohort of ovarian endometrioma, to understand their interactions in the pathophysiology of endometriosis and potential EAOCs. Similar to Study I, we also identified molecular heterogeneity with aberrant activation of TGF-β signalling as well as confirmed their anomalous behaviour using 3D spheroid and invasion assays in vitro. Interestingly, the above invasive phenotype could be altered by transient gene
knockdown of either SDC-1 or SDC-4 during active TGF-β signalling. Moreover, we showed that the presence of high levels of TGF-β ligands control endometriotic cell proliferation and reduce its 3D-spheroid invasive potential in vitro. Thus, inhibition of SDCs among subjects with aberrant TGF-β signalling could be suggested as a potential treatment strategy to reduce inherent risk towards EAOC.

In Study III, we examined the molecular action of selective progesterone receptor modulator, mifepristone among women with BRCA1 or BRCA2 mutations. Through in vitro studies, we confirmed the anti-proliferative action of mifepristone with inherent levels of progesterone among above cohort of BRCA1 or BRCA2 women, thus providing as an alternative preventive approach to avoid/delay the use of salpingo-oophorectomy in reducing ovarian cancer risk.

In Study IV, we demonstrated the mechanism of action for bromocriptine in the first known human clinical trial for the management of adenomyosis. Bromocriptine provided a prolactin mediated potent growth inhibition, reduced heavy menstrual bleeding as well as exhibited reversal of fibrosis, thus could be further explored for reversing the pathogenesis of adenomyosis.

**Conclusion:** To summarize, this thesis has demonstrated important molecular links underlying endometriosis and risk of EAOC. Also, this work has shown the possibilities for early detection and potential treatment strategies to reduce disease symptoms and/or inherent cancer risk.
I. Aberrant expression of genes associated with stemness and cancer in endometria and endometrioma in a subset of women with endometriosis
   Ponandai-Srinivasan S, Andersson KA, Nister M, Saare M, Hassan HA, Varghese SJ, Peters M, Salumets A, Gemzell-Danielsson K* and Lalitkumar PGL*
   *Human Reproduction, Vol.33, No.10 pp1924-1938, 2018

II. Syndecan inhibition reverses the pre-malignant phenotype of endometrioma with molecular heterogeneity through TGF-β signalling
   Manuscript

III. Mifepristone mediates anti-proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA1−/− carriers.

IV. Bromocriptine induces endometrial growth inhibition in women with Adenomyosis.
   Manuscript

* Equal contribution
CONTENTS

1 INTRODUCTION........................................................................................................ 1
  1.1 The Endometrium and the uterine cycle ................................................................. 1
  1.2 Benign gynecological disorders ............................................................................ 2
  1.3 Endometriosis ........................................................................................................ 3
    1.3.1 Prevalence of endometriosis ......................................................................... 4
    1.3.2 Diagnosis of endometriosis .......................................................................... 4
    1.3.3 Theories on the pathogenesis of endometriosis ........................................... 4
  1.4. Adenomyosis ....................................................................................................... 7
    1.4.1. Prevalence of adenomyosis ....................................................................... 7
    1.4.2. Diagnosis of adenomyosis ....................................................................... 8
    1.4.3. Theories on the pathogenesis of adenomyosis ........................................... 8
  1.5. Treatment strategies for endometriosis/adenomyosis ....................................... 10
    1.5.1. Laparoscopic surgery ................................................................................. 10
    1.5.2. Hormonal contraception .......................................................................... 10
  1.6. Endometriosis-associated ovarian cancers (EAOC) ..................................... 11
    1.6.1. Prevalence of EAOC ................................................................................. 12
    1.6.2. Histological markers of EAOC .................................................................. 12
    1.6.3. Molecular markers of EAOC .................................................................... 13
  1.7. BRCA1 or BRCA 2 MUTATIONS and ovarian cancer risk ............................ 14
    1.7.1. Prevalence of BRCA1 or BRCA2 mutations .......................................... 14
    1.7.2. Theories on the pathogenesis of BRCA1 or BRCA2 mutations and cancer development ........................................................................................................ 15
  1.8. strategies for reducing ovarian cancer risk among high-risk populations ...... 16
    1.8.1. Prophylactic surgery ............................................................................... 16
    1.8.2. Chemoprevention ..................................................................................... 16
  1.9. Endometrial stem cells ......................................................................................... 16
    1.9.1. Historical overview of endometrial SC ..................................................... 17
    1.9.2. Endometrial SC in regeneration and diseases .......................................... 17
    1.9.3. Markers for identifying endometrial SC .................................................... 18
  2. AIM AND OBJECTIVES ......................................................................................... 21
  3. METHODOLOGICAL CONSIDERATIONS .................................................... 23
    3.1. Patient cohorts and study design ..................................................................... 23
    3.2. Ethical considerations ..................................................................................... 24
    3.3. Isolation of CD90+CD73+CD105+stem/stromal cells ................................... 24
    3.4. Targeted PCR array and clustering analysis .................................................... 24
    3.5. Treatment doses ............................................................................................. 25
    3.6. Spheroid cultures ........................................................................................... 25
    3.7. Transcriptomic sequencing and analysis ......................................................... 26
  4. RESULTS AND DISCUSSION ............................................................................ 27
    4.1. Paper I ........................................................................................................... 27
      4.1.1. Eutopic and ectopic SC+ did not express ovarian CSC markers ......... 27
4.1.2. A subset of endometriomas aberrantly expressed stem- and cancer-related genes.

4.1.3. An aberrantly expressed endometriotic SC+ exhibited chemoresistance.

4.1.4. An aberrantly expressed endometriotic tissue had previous incidence of non-gynaecological cancers.

4.2. Paper II

4.2.1. A subgroup of endometriomas aberrantly expressed syndecans and molecules of TGF-β signalling.

4.2.2. In vitro activation of TGF-β signalling inhibited endometriotic cell growth and invasion.

4.2.3. A subset of endometriotic SC+ exhibited resistance to TGF-β induced growth inhibition.

4.2.4. Transient knockdown of SDC-1 and SDC-4 reversed the premalignant characteristics during active TGF-β signalling.

4.3. Paper III

4.3.1. Heterogeneity in PR levels and their clinical impact.

4.3.2. Anti-proliferative action for MIFE on BRCA1 or BRCA2 mutated ovaries.

4.3.3. Combined MIFE and P treatment reduced proliferation and p21 mediated cell cycle arrest.

4.4. Paper IV

4.4.1. Bromocriptine treatment reversed tissue injury and reduce cell activity.

4.4.2. Patients with good response to bleeding outcomes exhibited low expression of proliferation markers.

4.4.3. PRL expression correlated positively with ki67 and BAX.

5. CONCLUSIONS

6. STUDY LIMITATIONS

7. FUTURE DIRECTIONS

8. ACKNOWLEDGEMENTS

9. REFERENCES
LIST OF ABBREVIATIONS

3D  Three dimensional
aHR  Adjusted hazard ratio
ASRM  American society for reproductive medicine
BRCA1 or BRCA2  Breast cancer gene- 1 or 2
CHC  Combined hormonal contraceptives
CI  Confidence Interval
CSC  Cancer stem like cells
DNA  Deoxy ribo-nucleic acid
DE  Differentially expressed
E  Estrogens
E2  Estradiol
E2 cells  ER+ first-generation progenitors
E2-P cells  ER+ and PR+ second generation progenitors
EAOC  Endometriosis associated ovarian cancer
ECM  extracellular matrix
EMT  Epithelial mesenchymal transition
Endo  Endometrioma from women with endometriosis
EndoSC  Stem/stromal cells from endometrioma or endometriotic cyst
ER  Estrogen Receptor
ER-α  Estrogen receptor alpha
ER-β  Estrogen receptor beta
G2/M  cell cycle Gap2/Mitosis phase
H-En  Endometrium from healthy volunteers
HC  Hydrocortisone
HLA  Human Leukocyte Antigen
HMB  Heavy menstrual bleeding
HR
Hazard ratio

IUS
Intra uterine system

JZ
Junctional Zone

LH
Luteinising hormone

LNG
Levenogesterol

LS
Laparoscopic surgery

MIFE
Mifepristone

ml
millilitre

MRI
Magnetic resonance imaging

ng
nanogram

OR
Odds Ratio

P
Progesterone

P cells
PR+ third generation progenitors

P-En
Endometrium from women with endometriosis

P-EnSC
Stem/stromal cells from endometrium of endometriosis

P/LP
Pathogenic/less pathogenic variants

PBLAC
pictorial blood loss assessment chart

PCA
Principle component analysis

PCR
Polymerase chain reaction

PID
Pelvic inflammatory disease

Poly-A
Poly-adenylated sequence

PR
Progesterone Receptor

PRL
Prolactin

PRL-R
Prolactin receptor

rhTGF-β
Recombinant Transforming growth factor beta

RNA
Ribonucleic acid

RR
Relative risk

RRSO
Risk reducing salpingo-oophorectomy
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>SC</td>
<td>Stem cells or progenitors</td>
</tr>
<tr>
<td>SC−</td>
<td>Negatively sorted cells for makers CD90, CD73, CD105</td>
</tr>
<tr>
<td>SC+</td>
<td>Positively sorted stem/stromal cells for CD90, CD73, CD105</td>
</tr>
<tr>
<td>SDC-4</td>
<td>Syndecan-4</td>
</tr>
<tr>
<td>SDC1</td>
<td>Syndecan-1</td>
</tr>
<tr>
<td>SIR</td>
<td>Standardized incidence ratio</td>
</tr>
<tr>
<td>SMART-seq2</td>
<td>RNA sequencing protocol designed for single cell sequencing</td>
</tr>
<tr>
<td>SP</td>
<td>Side populations</td>
</tr>
<tr>
<td>SPRM</td>
<td>Selective progesterone receptor modulator</td>
</tr>
<tr>
<td>TGF-β</td>
<td>Transforming growth factor beta</td>
</tr>
<tr>
<td>TIAR</td>
<td>Tissue injury and repair mechanism</td>
</tr>
<tr>
<td>TVUS</td>
<td>Transvaginal ultrasound</td>
</tr>
<tr>
<td>µM</td>
<td>micro-molar</td>
</tr>
</tbody>
</table>
1 INTRODUCTION

1.1 THE ENDOMETRIUM AND THE UTERINE CYCLE

The inner lining of the uterus, known as the endometrium, has drawn increasing research attention in recent years due to its distinct role in women’s health and disease. It provides a cycle-dependent environment for the implantation of the blastocyst into the uterus to support foetal development (Guyton and Hall 2006). In women of reproductive age, the endometrium undergoes more than 400 cycles of well-coordinated events involving growth and differentiation as well as subsequent tissue shedding and remodelling, as depicted in Fig. 1.

Histologically, the endometrium comprises two distinct layers: the upper functionalis layer and the lower basalis layer. The functionalis layer comprises the luminal and glandular epithelium, surrounded by loose stroma. It regenerates to a thickness of about 4–10 mm at the follicular (or proliferative) phase due to a rise in estrogen (E) levels. The basalis layer is richly supplied with spiral arteries that have tubular glands and dense stroma (Guyton and Hall 2006). It has been reported that the amazing regenerating potential of the endometrium is due to the existence of active stem cells within the basalis layer, which repopulate the denuded functionalis layer during every menstrual cycle (Gargett and Masuda 2010; Schwab et al. 2005).

![Endometrium schematic diagram](image.png)

**Fig. 1 Schematic diagram on different phases in uterine cycle**
Endometrium undergoes a repetitive uterine cycles of tissue regeneration, differentiation, shedding and remodelling. E promote endometrial regeneration during follicular phase while P cause differentiation and prepares endometrium for implantation during luteal phase. In absence of successful implantation, menstrual phase occurs resulting in tissue shedding and remodelling. This image is reused with permission from Servier medical art, licenced by Creative Commons Licence 4.0.

In response to the surge in luteinising hormone (LH) from the pituitary gland, there is a shift from the follicular to the luteal (secretory) phase. The LH surge triggers ovulation from the
dominant ovarian follicle, which releases an oocyte. Consequently, the empty ovarian follicle develops into a hormone-secreting body called the corpus luteum, the role of which is to secrete and release progesterone (P). The rise in P levels alternates with a fall in E levels in the endometrial functionalis layer, priming it to a secretory decidualised phenotype. The endometrium becomes receptive during the mid-luteal phase (6-8 days after ovulation) known as the ‘window of implantation’, wherein it allows an embryo to implant. The implantation of a human embryo involves sequential events such as apposition, attachment and invasion of embryonic trophoblast cells through the uterine luminal epithelial cells. This process involves an exchange between the endometrium and the embryo of many molecules belonging to the family of cytokines, growth factors and hormones. Glands and blood vessels further grow in size; vascular spaces between them become interconnected to form the placenta, which supplies oxygen and nutrition to the developing foetus. If there is no fertilised oocyte or blastocyst implantation is unsuccessful, there is a rapid fall in P levels. This triggers a cascade of events involving constriction of blood vessels, necrosis and desquamation of the endometrial functionalis layer, leading to the onset of menstruation. The functionalis layer is shed from the uterine cavity during menstruation, leaving the basalis layer intact. (Guyton and Hall 2006; Padykula et al. 1984; Jabbour et al. 2006).

1.2 BENIGN GYNECOLOGICAL DISORDERS

Women’s reproductive health may be hampered by several gynaecological conditions that can place a heavy burden on quality of life, health and wellbeing. Although most benign disorders can be treated, a lack of knowledge about their specific symptoms or risk factors may prevent women from seeking help at the early stage of the disease. This drives the need for better understanding of symptoms and aetiologies for early diagnosis as well as the provision of suitable diagnostic, prophylactic and/or treatment measures. Benign gynaecological disorders can be broadly categorised into three groups: menstrual disorders, pelvic inflammatory disease and benign tumours/cysts.

(i) Menstrual disorders include amenorrhoea (no menstruation, which may also be a desired consequence of treatment), menorrhagia (abnormal bleeding at irregular intervals) and heavy menstrual bleeding (HMB, heavy but regular). Other symptoms related to benign gynaecological disorders may include dysmenorrhoea (painful menstruation), vaginal discharge and infertility. Both menorrhagia and HMB can lead to anaemia and severe iron deficiency, which result in chronic symptoms such as fatigue, poor wound healing and risk of infections (Black and Fraser 2012). Treatment may involve the use of hormonal
contraceptives, which might help in reducing excessive or irregular bleeding and dysmenorrhea.

(ii) Pelvic inflammatory disease (PID) is an acute microbial infection primarily caused by the disruption of the mucosal lining of the endocervical wall, which provides the means for potential pathogens to enter into the upper genital tract. As a consequence, these infections may spread to any of the pelvic organs such as the endometrium (endometritis), ovary (oophoritis) or uterine wall (myometritis) (Boyle and Torrealday 2008). PID typically appears as an indurated and oedematous uterus, with the presence of purulent material, ovarian abscess or tenderness, severe abdominal pain during motion/intercourse, HMB and vaginal discharge and fever. Oral or parenteral antibiotic regimens and sometimes surgery may be used for the treatment of PID and tubal-ovarian abscess (Wiesenfeld and Sweet 1993).

(iii) Benign tumours or cysts are formed as cellular outgrowth due to hormonal dysregulation (for instance, aberrant estrogen signalling) within the uterus or ovary. They proliferate slowly and rarely become cancerous (Boyle and Torrealday 2008). The most common types are uterine polyps and fibroids, which are formed in the endometrium or myometrium, respectively. On the other hand, a benign cyst can be formed on the ovary due to either an unruptured persistent follicle or corpus luteum (functional ovary cyst) or as a consequence of retrograde shedding of ectopic endometrial lesions on to the ovary (endometriosis or endometriotic cyst (endometrioma)).

In the context of this thesis, I will focus on two benign gynaecological conditions originating in the endometrium, namely (i) endometriosis and (ii) adenomyosis.

1.3 ENDOMETRIOSIS

Endometriosis is an estrogen-dependent, chronic inflammatory gynaecological disorder, characterised by the presence of endometrial-like tissue outside the uterine cavity that forms ectopic lesions or cysts. These lesions and cysts can be found in a wide variety of locations in the pelvis; however, they are most frequently found on the ovary, forming endometrioma or endometriotic cysts. Sometimes these lesions can penetrate the surface of the peritoneum, forming either superficial or deep infiltrating endometriosis. On rare occasion, they may be found on other distant anatomical sites such as the bladder, the kidneys, the lungs and even the brain (Starzinski-Powitz et al. 2001; Zhao et al. 2015; Pritts and Taylor 2003). Most women suffering from endometriosis experience symptoms such as dysmenorrhea (painful menstruation), dyspareunia (painful intercourse), pelvic pain and infertility (Vigano et al. 2004); there are a few asymptomatic (no symptoms) cases as well. Moreover, the risk of
endometriosis increases with reproductive health issues related to menstruation such as shorter cycle length, longer duration of menstrual flow and reduced parity. Conversely, the risk of endometriosis is increased with alcohol (Parazzini et al. 2013) and coffee consumption (Saha et al. 2017) and is decreased with other lifestyle factors such as exercise (Eskenazi and Warner 1997).

1.3.1 Prevalence of endometriosis
The exact prevalence of endometriosis is unknown since the clinical presentation can vary from asymptomatic and unexplained infertility to severe symptoms such as dysmenorrhoea and chronic pain. The prevalence has been estimated to be around 2%–10% among women of reproductive age and about 50–60% of women with either chronic pain or infertility or both (Eskenazi and Warner 1997; Goldstein et al. 1980; Meuleman et al. 2009). Moreover, endometriosis has a substantial effect on the psychological and social wellbeing of affected women and imposes a huge economic burden both on individuals and on society. For instance, in the United States, the economic burden has been estimated to be about 12,419 US dollars per woman among endometriosis patients (Simoens et al. 2012). In addition, a delay of 6.7 years has been projected between the onset of symptoms and diagnosis as well as around 10.7 hours lost per week per woman affected, in terms of productivity due to chronic disease symptoms (Rogers et al. 2013).

1.3.2 Diagnosis of endometriosis
There are no validated, non-invasive biomarkers for endometriosis. Currently, diagnosis is made through laparoscopic surgery and subsequently verified by histological or pathological examination. In addition, transvaginal ultrasound (TVUS) and/or magnetic resonance imaging (MRI) can be suggested. The American Society for Reproductive Medicine (ASRM) has put forth some guidelines for the diagnosis of endometriosis (American Society for Reproductive Medicine: Revised classification of endometriosis 1997), including the presence of endometrial-like cells on target tissues, accompanied by specific features such as adhesion of lesions on the peritoneal wall or ovarian surface, and cyst diameter as well as the presence of thick, chocolate-coloured fluid content within the cyst. Based on the above features, ASRM has categorised the severity of endometriosis into several stages: minimal (stage 1), mild (stage 2), moderate (stage 3) and severe (stage 4).

1.3.3 Theories on the pathogenesis of endometriosis
Endometriosis is considered a multi-factorial disease, the aetiology of which is not fully understood. Several predisposing factors have been proposed regarding its pathogenesis, which
could be explained using the ‘two-stage’ theory: initiation and promotion (Parazzini et al. 2016). The initiation phase of the disease is triggered by factors such as early menarche, menstrual cycle length, duration/volume of menstrual flow and parity. Later, promotion factors such as immune dysfunction, haeme, free iron-induced oxidative stress, impaired progesterone synthesis and apoptosis suppression together with aberrant estrogen secretion, support vascularisation and promote growth (Kobayashi et al. 2008). The above hypothetical model for endometriotic lesion development is illustrated in Fig. 2.

![Fig. 2. Schematic diagram of the role of stem cells in the pathogenesis of ovarian endometriosis.](image)

Endometrial cells including SCs were shed by retrograde menstruation to peritoneal cavity, where they get adhered, implanted and establish endometriotic lesions. Due to immunological, genetic and microenvironmental factors, some of the endometriotic cells might gain mutations or gene alterations causing altered cellular phenotype. This picture was originally self-drawn, now modified and reprinted from Paper-I (Ponandai-Srinivasan et al. 2018). Permission to reuse was provided by Rights Link Copyright clearance centre.

Two important theories will be discussed in relation to the studies involved in this thesis.

**A. Retrograde menstruation theory**

Samson’s retrograde menstruation was the oldest and most accepted theory for the pathogenesis of endometriosis. According to this theory, as a consequence of occasional retrograde menstrual flow, endometrial tissue was shed into the peritoneal cavity and later adhered to the surface of the peritoneum or ovaries, forming ectopic endometrial lesions (Sampson 1927). Experimental evidence from non-human primates showed that endometriosis could possibly be induced by inoculating autologous menstrual products into the peritoneal cavity (D’Hooghe et al. 1994). In addition, the lesions developed from these models were histologically and clinically similar to the endometriotic lesions occurring on the ovary or peritoneal sites of humans (D’Hooghe 1997). It was suggested that obstructive menstrual disorders such as iatrogenic cervical stenosis (narrowing of the passageway through the cervix)
or congenital menstrual disorders might also increase the risk of retrograde menstruation (Burney and Giudice 2012). However, this theory fails to explain why only 10% of women have endometriosis even though retrograde menstruation has been observed among 76–90% of women (Sasson and Taylor 2008). Furthermore, it does not explain how endometriotic lesions can be localised in the lungs, brain, etc.

B. **Stem cell theory**

The immense regenerative potential of the endometrium during menstrual bleeding and the re-epithelisation of the endometrium after childbirth or surgical curettage support the theoretical existence of stem cells (SC) in the endometrium. Adult SC are undifferentiated cells, which have the capacity to self-renew upon external stimuli as well as induce differentiation to attain a cell-type-specific phenotype with a designated function (Gargett and Masuda 2010). Accordingly, researchers have identified adult SC within a highly regenerative endometrium (Meng et al. 2007; Gargett et al. 2016), menstrual fluid, peritoneal fluid (O et al. 2017) and endometriotic lesions (Gargett and Chan 2006; Gargett et al. 2014; Silveira et al. 2012). Clonogenic cells have been identified that express markers of stemness in a long-term culture derived from endometriotic lesions, which supports to their role in the pathogenesis of endometriosis (Silveira et al. 2012). Moreover, it has been suggested that hyperperistalsis in the uterus is associated with the development of endometriosis (Leyendecker et al. 2004). As a consequence of hyperperistalsis, endometrial basalis tissue is shed abnormally by retrograde menstruation into the peritoneal cavity; once there, the fragments exhibit increased potential to implant and proliferate due to higher E levels as well as estrogen receptor (ER) and progesterone receptors (PR). In addition, it has been shown that differentiated stromal fibroblasts from women with endometriosis inherit the progesterone resistance and pro-inflammatory phenotype from their SCs (Barragan et al. 2016). It has further been suggested that ectopic endometriotic SCs have more invasive and migratory capacity relative to eutopic endometrial SCs, studied using both *in vitro* (Sundqvist et al. 2012) and *in vivo* models (Kao et al. 2011); angiogenesis has also been stimulated. Experts in the field recently proposed that the endometrial SC might be shed during uterine bleeding among neonatal girls and that the SC remain quiescent within the peritoneal cavity for several years (Brosens et al. 2013). Later, if these quiescent cells get reactivated during adolescence due to the function of ovarian hormones, it may also facilitate implantation and establishment of endometriotic lesions (Gargett et al. 2014; Puttemans et al. 2016). However, certain SC populations may develop somatic mutations and gene deregulations due to prolonged exposure to immunological and environmental stress, to attain pre-malignant potential (Gadducci et al. 2014; Gargett et al. 2014).
1.4. ADENOMYOSIS

Adenomyosis, previously called endometriosis interna, is a common, benign gynaecological condition, observed in 19.5% of women in reproductive age (Devlieger et al. 2003; Garcia-Solares et al. 2018). Women with adenomyosis present non-specific symptoms similar to those of endometriosis or uterine fibroids such as abdominal pain, HMB and infertility. At the beginning of the nineteenth century, all abdominal disorders involving mucosal invasion were considered to be ‘adenomyoma’ (Benagiano et al. 2009) since they share several features in terms of symptomology, histology and molecular alterations (Leyendecker et al. 2015). Later, Frankl (Frankl 1925) created the word ‘adenomyosis’ to describe the presence of ectopic endometrial tissue inside the uterine myometrium (Ferenczy 1998). Two years later, Sampson (Sampson 1927) proposed retrograde menstruation theory to describe the mechanism of peritoneal endometriosis. However, since Samson’s theory does not explain the mechanism of endometrial invasion inside the myometrium, adenomyosis and endometriosis have been considered to be two separate conditions ever since (Benagiano and Brosens 2006, 2011). Women with adenomyosis usually have early menarche, shorter menstrual cycles, increased body mass index, are multiparous, relatively older in age and have a history of induced abortion (Parazzini et al. 2009; Templeman et al. 2008).

1.4.1. Prevalence of adenomyosis

Several reports have suggested a strong association between endometriosis and adenomyosis. Both conditions have been closely linked with molecular changes or abnormalities occurring either on the inner portion of the myometrium or at the junctional zone (JZ) between the endo- and the myometrium, leading to a highly migratory and invasive eutopic endometrium (Benagiano et al. 2014). Adenomyosis has been observed in 34.6% of cases having deep infiltrating endometriosis while a reference group without endometriosis had an incidence of only 19.4% (Bazot et al. 2004). In another study, 40% of endometriosis cases showed irregular JZ, as opposed to 22.5% in the non-endometriosis group. In terms of older women (40–50 years) undergoing surgery for either adenomyosis or uterine fibroids, 34.1% showed co-existence of endometriosis (Naphatthalung and Cheewadhanaraks 2012). In addition, there was a specific correlation reported between adenomyosis and deep infiltrating endometriosis (Gonzales et al. 2012) as well as with a group possessing concomitant endometriosis and infertility (Kunz et al. 2005). However, it is important to note that most of the above studies included cases of co-existing endometriosis with adenomyosis due to a lack of clear guidelines or diagnostic criteria for distinguishing between them. As a result, the reported frequency of adenomyosis were higher than the real incidence.
1.4.2. Diagnosis of adenomyosis

Adenomyosis is traditionally diagnosed by histological examination following hysterectomy (Morassutto et al. 2016). The pathological examination may present as an enlarged, globular uterus with areas of hypertrophic and hyperplastic myometrial smooth muscle, along with the presence of dark cysts within the myometrium. Histologically, it is visualised by the invagination of endometrial glands and stroma through the JZ into the myometrium, as well as adjacent myometrial hyperplasia, which causes globular and cystic enlargements in the myometrium (Donnez et al. 2018). With the advent of non-invasive imaging techniques such as TVUS and MRI, it is now possible to differentiate features specific to adenomyosis and not endometriosis, such as diffuse thickening of the inner myometrium, irregular JZ, the presence of localised lesions or an increased JZ-to-outer-myometrial ratio (Levy et al. 2013). Moreover, adenomyosis may present in two forms, focal or as a diffused, tumour-like growth. A focal lesion, also called adenomyoma, might be observed when a circumscribed nodular formation appears on the myometrium, while a diffuse form shows a uniform spreading of endometriotic glands and stroma throughout the surface and the depth of the myometrium (Gordts et al. 2018).

1.4.3. Theories on the pathogenesis of adenomyosis

Similar to endometriosis, the aetiology and pathogenesis of adenomyosis remains largely unknown. Here, I will discuss three important theories, namely: Invagination theory, metaplasia theory, and De novo stem cell theory.

A. Invagination theory

Invagination theory is the most widely accepted theory for the pathogenesis of adenomyosis. It suggests that adenomyosis may occur due to the invagination of endometrial glands from the basalis layer of endometrium into a traumatised endometrial-myometrial interface via tissue injury and repair (TIAR) mechanism, as depicted in Fig. 3A. Several studies have been performed to understand the cause and consequences of this mechanism. First, uterine peristalsis cause microtrauma to the JZ; however due to hypoestrogenism, there is an elevated oxytocin-mediated uterine peristalsis, which further cause auto-traumatisation and induce TIAR mechanism in a repetitive cycle (Leyendecker et al. 2015; Leyendecker et al. 2009). In addition, small nerve fibre injury inside the uterus during difficult intrapartum episodes has also been suggested as the cause of this disease (Quinn 2011). Studies measuring intrauterine sinusoidal pressure waves of varying frequencies during menstruation have suggested that the highest level of stress prevails on the endometrial-myometrial interface, which might induce molecular alteration; this, in turn, leads to the invasion of endometrial cells from the basal layer.
(Shaked et al. 2015). It has been claimed that the use of repeated sharp curettage causes disruption of the endometrial-myometrial border, thereby increasing the incidence of adenomyosis (Curtis et al. 2002; Levgur et al. 2000).

B. Metaplasia theory
This theory suggests that metaplastic changes occur on embryonic pluripotent Mullerian remnants could potentially establish de novo ectopic endometrial lesions at the intra-myometrial sites (Garcia-Solares et al. 2018), as shown in Fig. 3B.

C. Stem cell theory
According to this theory, repeated tissue injury and microtrauma at the IZ, induces activation of stem cells and an alteration in its niche (Vannuccini et al. 2017; Gargett et al. 2016). As a consequence, progenitor cells are allowed to differentiate in a retrograde direction by breaching the endometrial-myometrial interface and establish de novo adenomyosis lesions, as shown in Fig. 3C. It has also been postulated that multipotent cells from bone marrow and other sources may form de novo focal lesions inside the myometrium. Even though the invagination theory is the most widely accepted, de novo lesions from different sources might be a plausible mechanism. Hence, more studies are required to further establish the role of endometrial SC or Müllerian remnants in the initiation of this disease.

Fig. 3. Theories on the pathogenesis of endometriosis. Adenomyosis are formed due to displacement of endometrial-like cells or tissues into uterine myometrium, which might be explained by (A) Invagination theory (B) Metaplasia theory (C) stem cell theory (reprinted from (Garcia-Solares et al. 2018) and permission for reuse provided by RightsLink Copyright clearance centre).
1.5. TREATMENT STRATEGIES FOR ENDOMETRIOSIS/ADENOMYOSIS

There are no disease-specific treatment options available for either endometriosis or adenomyosis. The treatments suggested so far have focused on alleviating the disease symptoms such as pelvic pain, abdominal cramps and HMB. Both disorders are estrogen-dependent, implying that the treatment should be targeted at suppressing excess E production and overcoming P resistance (Vercellini et al. 2014), thereby promoting fertility (Tsui et al. 2014). It is important to note that adenomyosis has not been as extensively researched as endometriosis.

1.5.1. Laparoscopic surgery

Laparoscopic surgery (LS) is the most common mode of treatment for the management of endometriosis. LS is performed to remove visible regions of endometriotic lesions or cysts either by using an ablation technique, which involves the destruction of a lesion by burning, or an excision technique, which implies cutting the lesion out surgically. A Cochrane review suggests that LS is moderately associated with reducing overall pain (odds ratio (OR): 6.58, 95%; confidence interval (CI): 3.31 to 13.10), improving live birth (OR: 1.94, 95%; CI: 1.20 to 3.16) and clinical pregnancy rate (OR: 1.89, 95%; CI: 1.25 to 2.86) (Duffy et al. 2014). Thus, it is very useful to provide relief for pain symptoms and sub-fertility. It is also important to remove active deposits of the ectopic lesions that caused pain symptoms. Unfortunately, treatment by LS alone may not be sufficient as these lesions tend to recur in cases of severe endometriosis (ASRM II/IV).

1.5.2. Hormonal contraception

Combined hormonal contraception (CHC) are widely used to treat women with pain associated with endometriosis (Jensen et al. 2018). To be effective, they should be used without a break (the so called ‘long cycle treatment’) and can be administered in the form of a pill, a patch or a vaginal ring. Continuous administration of CHC significantly reduces bleeding, dysmenorrhea, pelvic pain, dyspareunia and postoperative disease recurrence; and improve the overall quality of life (Vercellini et al. 2014; Grandi et al. 2019). The disadvantages of such treatment include contraindications to estrogen such as the increased risk of venous thromboembolism (Ferrero et al. 2010).

Treatment with progestins results in dose-dependent effects on follicular development and ovulation; as well as cervical mucus. They also act on all organs with PR, including the endometrium. Progestins promote decidualisation and atrophy of the endometrium and endometrial implants. Progestins in various forms reduce vaginal bleeding and provide
resolution from pain symptoms associated with endometriosis (Brown et al. 2012). The levonorgestrel-releasing intrauterine system (52 mg LNG-IUS) is a safe, highly effective and accepted reversible, long term contraceptive method as well as an effective treatment for uterine disorders such as endometriosis or adenomyosis related pain and HMB (Gemzell-Danielsson et al. 2011). High local concentrations of LNG provided by the IUS in the endometrium and to a lesser degree in the myometrium results in decidualisation and endometrial atrophy, usually without suppressing ovulation (dose-dependent effect).

Selective progesterone receptor modulators (SPRM, such as ulipristal acetate, mifepristone, and vilaprisan, exert an agonist, antagonist or mixed effect due to their competitive action with P on PRs. SPRMs were developed for the treatment of endometriosis and studied for the treatment of adenomyosis; they are also available for the short-term treatment of uterine fibroids (Whitaker et al. 2017; Schutt et al. 2018; DeManno et al. 2003).

Other treatment possibilities include aromatase inhibitors (Ferrero et al. 2011) and selective estrogen receptor modulators. The latter act as antagonists on ER, thereby inhibiting endometrial proliferation and inducing atrophy (Tsui et al. 2014). Also, gonadotropin releasing hormone agonists (such as buserelin, goserelin, leuprolide, nafarelin, and triptorelin), are effective in inducing amenorrhea and reducing pain. However, hypoestrogenic side effects limit their use unless an add-back therapy is given (Tsui et al. 2014).

1.6. ENDOMETRIOSIS-ASSOCIATED OVARIAN CANCERS (EAOC)

Endometriosis is generally considered a benign disorder; however, on rare occasion, it may exhibit certain characteristics of malignancy such as uncontrolled growth, neo-angiogenesis, local invasion and migration (Munksgaard and Blaakaer 2012; Starzinski-Powitz et al. 2001). Several epidemiological studies have consistently shown endometriosis carries an increased risk for various malignancies (Kok et al. 2015; Munksgaard and Blaakaer 2012); the strongest association was observed for ovarian cancer, known as endometriosis-associated ovarian cancer (EAOC) (Melin et al. 2006; Lundberg et al. 2019; Saavalainen et al. 2018; Pearce et al. 2012). A meta-analysis conducted on EAOC estimated that about 80% of reported cases were of ovarian origin (Heidemann et al. 2014; Kim et al. 2014) and the remaining 20–25% were on extragonadal sites such as a peritoneal cavity, lower pelvis, gastrointestinal tract, abdominal wall, umbilicus, recto-vaginal septum, colon, pleura and others (Heaps et al. 1990; Irvin et al. 1998; Brooks and Wheeler 1977).
1.6.1. Prevalence of EAOC

A recent population-based cohort study showed an increased incidence of EAOC among women diagnosed with both endometriosis and infertility (adjusted Hazard risk (aHR) ratio: 2.19, 95%CI 1.70 – 2.82) compared to women diagnosed with only endometriosis (aHR: 1.77, 95%CI 1.53 – 2.05) or infertility (aHR: 1.53, 95%CI 1.36 – 1.72) (Lundberg et al. 2019). Moreover, endometriosis shows an increased risk, specifically towards the endometrioid (standardised incidence ratio (SIR): 2.26) and clear cell (SIR: 3.95) subtypes of ovarian cancers (Brinton et al. 2005; Saavalainen et al. 2018; Pearce et al. 2012). Moreover, Saavalainen et al. (2018) performed a sub-analysis based on the type of endometriosis (ovarian, peritoneal and deep infiltrating) and the independent risk of each endometriosis type towards different types of genital cancers (ovary, cervix, endometrial, etc.) (Saavalainen et al. 2018). Interestingly, there was a strong association reported between incidence of ovarian cancer among women with ovarian endometriosis (SIR: 2.56 (1.98–3.27)), specifically for the endometrioid (SIR: 4.72 (2.75–7.56)) and clear cell (SIR: 10.1 (5.5-16.9)) sub–types. However, women with both peritoneal endometriosis (SIR: 1.32 (0.99–1.72)) and deep infiltrating endometriosis (SIR: 1.41 (0.29–4.1)) showed no increase in the overall risk for ovarian cancer. In addition, the risk of endometrial cancer was not altered in any type of endometriosis.

1.6.2. Histological markers of EAOC

Several chronological events have been documented that support a strong link between endometriosis and the development of ovarian cancer. Based on microscopic observations, Sampson (1925) proposed a set of criteria for the diagnosis of ovarian cancer in women with endometriosis; these criteria were as follows: (i) clear evidence of endometriosis close to tumour; (ii) demonstration of cancer arising within or from endometrioma, but not from anywhere else; and (iii) histological identification of tissue resembling endometrial stroma surrounding characteristic epithelial glands. is decreased with lifestyle factors such as exercise (Eskenazi and Warner 1997). Later, Scott (1953) elucidated an additional criterion: evaluation of the morphological changes that continuously occur within the epithelium during transformation from benign to malignant in endometriosis (Scott 1953). Currently, the above four histological criteria are used for diagnosing the transition from benign to malignant conversion in ovarian endometriosis (Tanase et al. 2013).

Several histological pieces of evidence suggest that EAOC may originate from atypical endometriosis of the ovary (Fukunaga et al. 1997; Czernobilsky and Morris 1979). Atypical endometriosis has been characterised as being similar to hyperplasia of the endometrial glands with cytological atypia (Clement 2007; Seidman 1996) and has been detected in 80% of EAOC
cases (Fukunaga et al. 1997; Worley et al. 2013). It possesses some unique features, such as eosinophilic cytoplasm, large hyperchromatic or pale nuclei with moderately marked pleomorphism, an increased nuclear-to-cytoplasmic ratio, cellular crowding and stratification or tufting. It has also been suggested that other factors, such as genetic, immunological, environmental (including microenvironmental) and cytokines play a key role in the malignant transformation of endometriosis to EAOC (Worley et al. 2013; Varma et al. 2004).

1.6.3. Molecular markers of EAOC

In the past two decades, numerous studies have consistently shown that EAOC may arise from genetic alterations that occur within an endometrioma due to the altered peritoneal microenvironment. One possible explanation might be the accumulation of haeme, free iron and reactive oxygen species from menstrual reflux, which may induce oxidative stress and develop mutations in key genes. Yamaguchi et al. (2008) showed that the concentration of free iron was significantly higher in endometriotic cysts compared to non-endometriotic cysts. In addition, endometriotic cyst fluid also expressed high levels of reactive oxygen species such as 8-hydroxy-deoxyguanosine similar to the levels observed in carcinomas (Yamaguchi et al. 2008) and their higher levels were associated with poor prognosis in epithelial ovarian cancer (Pylvas et al. 2011). Furthermore, an impaired immune response may also cause chronic inflammation and macrophage or aberrant cytokine activation, which would trigger mutations within endometrioma (Gazvani and Templeton 2002).

Alternatively, there might be inherent mutations in eutopic endometrial cells among susceptible subjects due to family history or impaired hormonal activity. They may also add more mutations as a consequence of local inflammation or altered niche within endometriotic cysts during retrograde flow. Some of the common somatic mutations and genomic aberrations reported during malignant transformation of EAOC include: silencing of the key tumour suppressor genes TP53 (Sainz de la Cuesta et al. 2004; Akahane et al. 2007), PTEN (Govatati et al. 2014) and ARID1A (Wiegand et al. 2010); oncogene activation of KRAS (Amemiya et al. 2004; Stewart et al. 2012), PIK3CA and CTNNB1 (McConechy et al. 2014) and downregulation of BCL2 (Nezhat et al. 2002; Akahane et al. 2007). A study analysing deep infiltrating endometriotic lesions with no risk of EAOC demonstrated several mutations in cancer-driver genes, such as ARID1A and PI3KCA (Anglesio et al. 2017), that were commonly mutated in both clear cell ovarian carcinomas and concurrent endometriotic lesions (Anglesio et al. 2015). Moreover, EAOC cases also show loss of BAF250a expression, a protein encoded by ARID1A, especially within areas of contiguous endometriosis or atypical endometriosis
surrounding the tumour; this implies their expression has a role in the early stages of malignant transformation of endometriosis (Stamp et al. 2016).

Furthermore, the DNA mismatch repair genes hMLH1 or hMLH2 were also inactivated by hypermethylation within endometriotic tissue (Esteller et al. 1999). In some cases, aneuploidy in the advanced stages of endometriosis was reported, particularly along chromosome 17, on which tumour suppressor gene TP53 resides (Kosugi et al. 1999). Moreover, microsatellite analysis performed with EAOC patients showed a loss of heterozygosity among both cancerous and benign endometriotic lesions from the same patient, indicating endometriosis might be a clonal precursor to a subtype of ovarian cancer (Sato et al. 2000). This also implies that the molecular mechanisms that accompany the changes in EAOC might be different from ovarian cancer developed without a history of endometriosis. Hence, there is a need for a better understanding of its pathogenic mechanisms in order to develop specific prophylactic measures and avoid potential tumour growth among EAOC patients.

1.7. **BRCA1 OR BRCA 2 MUTATIONS AND OVARIAN CANCER RISK**

The breast cancer gene 1 (BRCA1) and gene 2 (BRCA2), are tumour suppressor genes that play a key role in monitoring DNA damage response and repair of DNA double-strand breaks by homologous recombination. However, cells that bear mutations in BRCA1 or BRCA2 repair DNA lesions via an alternative error-prone mechanism that leads to genomic instability and increased risk of breast and ovarian cancers (Stoppa-Lyonnet 2016).

1.7.1. **Prevalence of BRCA1 or BRCA2 mutations**

Hereditary mutations constitute around 15–20% of all cases of ovarian cancers; mutations on BRCA1 or BRCA2 are the major contributors (65–85%) within that category (Norquist et al. 2016). Pathogenic BRCA1 or BRCA2 mutations have been observed in 20% of high grade serous cancers, and 8% with clear and endometrioid histological subtypes of ovarian cancers (Alsop et al. 2012). Moreover, the lifetime risk for developing breast cancer due to BRCA1 or BRCA2 mutations has been estimated to be around 50–80%. With regard to ovarian cancer, the lifetime risk has been individually estimated to be around 30–60% and 10–25% due to BRCA1 and BRCA2 mutations (Kuchenbaecker et al. 2017). In addition, it has been observed that the age at diagnosis for ovarian cancer with BRCA1 or BRCA2 mutations is older than that of breast cancer; for instance, the mean age for BRCA1 and BRCA2 mutation is around 40–60 years and 50–70 years respectively (Finch et al. 2014). In addition, both these mutations increase the risk of other cancers such as BRCA1 for fallopian tube cancer and primary peritoneal cancer, and pancreatic cancer, prostate and breast cancer among BRCA2 mutation carriers.
In a general, unselected ovarian carcinoma cohort, 19% of cases were observed to have pathogenic and less/likely pathogenic (P/LP) germline variants of the BRCA1 or BRCA2 mutations (Maistro et al. 2016). Another cross-sectional study that screened for the prevalence of P/LP variants showed five times more individuals with P/LP variants by next-generation sequencing than previously detected based on personal or family history (Manickam et al. 2018); this indicates the need for genetic screening to identify BRCA1 or BRCA2 mutation carriers with potential cancer risk.

1.7.2. Theories on the pathogenesis of BRCA1 or BRCA2 mutations and cancer development

The association between BRCA1 or BRCA2 germline mutations and its potential cancer risk can be explained based on Knudson’s ‘two-hit’ hypothesis (Knudson 1971). According to the hypothesis, each tumour suppressor gene must undergo two hits (mutations) in its allelic pair in order to develop cancer (Knudson et al. 1975). With hereditary cancers, one of the hits is a germline mutation observed in all somatic cells, while the occurrence of the second hit is a deletion of a wild-type allele within the somatic cells of the target tissue. Accordingly, it has been shown that women with the BRCA1 mutation bear one inherited mutant allele and another wild-type BRCA1 allele. However, in most cancers, the wild-type allele is deleted, leaving no functional BRCA1 gene (Merajver et al. 1995). In this model, the inheritance pattern is autosomal-dominant, meaning that the mutant BRCA1 or BRCA2 allele was inherited from the previous generation. With respect to molecular expression, however, the BRCA1 or BRCA2 gene exhibits a recessive pattern since both the alleles need to be downregulated or inactivated to form a tumour (Rosen 2013).

Moreover, the relationship between BRCA1 or BRCA2 and TP53 also plays a critical role in the pathogenesis of breast and ovarian cancers. BRCA1 or BRCA2 interacts with tumour suppressor TP53 and regulates DNA damage response as well as cell-cycle checkpoint activation, especially through CHK1, which blocks cell-cycle progression in the Gap 2/Mitosis (G2/M) phase. With BRCA1 or BRCA2 deficiency, it has been suggested that TP53 and p21 are activated to regulate genomic instability, resulting in cell-cycle arrest or senescence. As expected, the incidence of TP53 mutations is higher among BRCA1 mutated cancers (>80%) compared to sporadic cancers (25%) (Holstege et al. 2009). Jiang et. al. (2011) reported that TP53 mediates the nuclear transport of BRCA1 by disrupting the BRCA1-BARD complex; hence, TP53 mutations among BRCA1 mutated carriers might amplify their chromosomal abnormalities due to repeated error-prone DNA damage response, which leads to increased incidence of breast or ovarian cancer.
1.8. STRATEGIES FOR REDUCING OVARIAN CANCER RISK AMONG HIGH-RISK POPULATIONS

Women with high risk for ovarian cancer were suggested with various risk-reducing strategies, which might vary in their effectiveness and potential side effects. Here, I will be discussing the important prevention strategies, namely prophylactic surgery and chemoprevention.

1.8.1. Prophylactic surgery

Risk reducing Salpingo-oophorectomy (RRSO) shows decreased risk of breast and ovarian cancer (Domchek et al. 2010; Rebbeck et al. 2009) as well as improved overall survival (Eleje et al. 2018) among women with BRCA1 or BRCA2 mutations. However, RRSO were accompanied by adverse effects such as infertility, sexual dysfunction, premature menopause and increased morbidity; in addition, they had a negative impact on body image and quality of life (Domchek et al. 2010; Madalinska et al. 2005; Rocca et al. 2006). Alternatively, reduced cancer risk with limited side effects was reported with the use of prophylactic salpingectomy with ovarian retention (Carcangiu et al. 2006; Finch et al. 2006) and tubal ligation (sterilisation) (Kjaer et al. 2004; Sieh et al. 2013). In addition, it has been suggested that combination strategies such as hysterectomy plus RRSO (Hazard ratio (HR): 0.06) provide better protection compared to the use of either tubal ligation (HR: 0.72) or hysterectomy (HR: 0.79).

1.8.2. Chemoprevention

It has been suggested that CHCs reduce the risk of epithelial ovarian cancers among both the general (EAOC) and the high-risk population (BRCA1 or BRCA2 carriers) and that their protective effect is improved with long-term use (Havrilesky et al. 2013; McLaughlin et al. 2007; Iodice et al. 2010). SPRMs such as mifepristone (MIFE) also show promising results in experimental settings for reducing or delaying the use of RRSO or inherent cancer risk. For instance, mifepristone (MIFE) has been shown to prevent mammary tumorigenesis in an animal model of the BRCA1 mutation (Poole et al. 2006). In addition, clinical studies examining a low dose of MIFE exhibited a favourable, anti-proliferative effect on breast tissue in premenopausal women (Engman et al. 2008). On other hand, the use of non-steroidal anti-inflammatory drugs and aspirin show diverse effects in several epidemiological studies.

1.9. ENDOMETRIAL STEM CELLS

The human endometrium is a highly regenerative organ which regrows from a thickness of 1–2 mm just after menstrual shedding to its full thickness of more than 14 mm during the secretory phase of the menstrual cycle. Considering the immense regeneration potential, it has been suggested that endometrial tissue might contain a population of SC with a capacity to self-
renew and produce differentiated cells indefinitely, in order to restore the endometrium after every menstrual cycle.

1.9.1. Historical overview of endometrial SC

Prianishnikov was the first to postulate the existence of SC (Prianishnikov 1978). Over a decade ago, a rare clonogenic population was identified within pure epithelial and stromal cells that has the capacity to form colonies and differentiate into mesenchymal lineages (Chan et al. 2004). Subsequently, a putative cell population, known as label-retaining cells were identified, that can retain bromodeoxyuridine after their incorporation into a mouse endometrium (Chan and Gargett 2006). Consequently, another form of clonogenic cells known as endometrial side populations (SP) were identified, which efficiently efflux Hoechst dye (Cervello et al. 2011). These SP cells were able to exhibit self-renewal and multi-lineage differentiation capacities in vitro as well as undergo tissue reconstitution in vivo. Concurrently, Taylor (2004) reported that the HLA-mismatched bone-marrow derived stem cells from donors were successfully engrafted into the recipient endometrium, suggesting that the endometrium could be regenerated from non-uterine stem cells (Taylor 2004). Subsequently, the putative stem cells were suggested to be of hematopoietic origin and postulated their key role in endometrial regeneration and disease pathologies (Du and Taylor 2007).

1.9.2. Endometrial SC in regeneration and diseases

Prianishnikov suggested a model on hierarchical hormone responsiveness for the regeneration of endometrial cells during each uterine cycle (Prianishnikov 1978). According to the model, endometrial SCs are located deep inside the epithelium of the basalis endometrium and may not be subjected to any destruction during menstrual bleeding. These SC are a very small pool of hormone-independent cells (Ferenczy 1976) and their proliferation is chiefly regulated by microenvironmental factors as a consequence of tissue injury. Upon SC division, first-generation progenitor cells (E2-cells) are formed, which express ER in response to raising E2 levels in the uterine cavity. Concurrently, the second-generation daughter cells (E2-P cells), unlike E2-cells, are formed during the later stage of the proliferative phase and become responsive to both P and E2 by expressing both ER and PR. Subsequently, E2-P cells further divide in response to higher P levels in the secretory phase; they later undergo terminally differentiated P cells with decidualised cellular phenotype. During menstruation, only P-cells residing in the functionalis layer are denuded from the endometrial surface, leaving their predecessors intact. The above model is illustrated in Fig. 4.
Fig. 4. Postulated model on the involvement of stem cells in endometrial regeneration

Stem cells and its progenitors are influenced by estrodiol (E2) and progesterone (P) resulting in the formation and distribution of various cell types at different stages of uterine cycle. Abbreviations (ST-cell=stem cell; E2-cell=ER+ progenitors; E2P-cell= both ER+ and PR+ progenitors; P-cell= PR+ differentiated cells). The image is reused from (Tempest, Maclean, et al. 2018) and permission for reuse provided by Creative Commons 4.0.

However, due to constant and prolonged stimulation of E2, which alternates with insufficient P levels in the uterus, the equilibrium of the above processes may be disturbed; this may have potential implications in proliferative uterine disorders such as endometriosis or adenomyosis. Also, it was proposed that the functionalis endometrium in women with endometriosis possesses a high percentage of ‘basalis-like cells’ that are subsequently shed via retrograde menstruation and contribute to the initiation of ectopic endometriotic implants (Leyendecker et al. 2002). The above theory remains unproven since it is not possible to differentiate between cells originating in the basalis layer and those originating in the functionalis layer.

1.9.3. Markers for identifying endometrial SC

It has been suggested that putative SC from the endometrium are formed from heterogeneous cell clusters, including stromal, epithelial and endothelial progenitors, as depicted in Fig. 5. It has been hypothesised that epithelial progenitors in the basal compartment initiate the regeneration to form differentiated luminal and glandular epithelial cells. However, it has been challenging to identify endometrial epithelial SC due to a lack of specific markers as well as techniques to culture and maintain epithelial cells for longer duration in vitro. As of now, epithelial SC activity has been demonstrated for markers SSEA-1 (Hapangama et al. 2019; Valentijn et al. 2013), SOX9 (Tempest, Maclean, et al. 2018; Hapangama et al. 2019), N-
cadherin (Nguyen et al. 2017), Musachi-1 (Gotte et al. 2008; Tempest, Baker, et al. 2018), LGR5 (Tempest, Baker, et al. 2018) and in a small proportion of previously characterised SP cells (Cervello et al. 2011; Masuda et al. 2010). In addition, it has been suggested that characterised SP cells are predominantly of endothelial origin (Cervello et al. 2011; Masuda et al. 2010). On the other hand, stem cells of stromal/mesenchymal origin are usually fibroblast-like and reside within the perivascular space along with loose stroma in the basalis layer of the endometrium. Some suggested markers with confirmed stem cell properties are as follows: CD146+, PDGF-Rβ+ (Schwab and Gargett 2007), W5C5/SUSD2 (Masuda et al. 2012), CD44, CD29, CD73, CD90 and CD105 (Meng et al. 2007; Gargett et al. 2009; Dominici et al. 2006).

![Fig.5. Schematic diagram on the postulated location of endometrial progenitors in the human endometrium.](image-url) Putative stem cells were supposed to be formed in basalis region of endometrium and composed of stromal (CD140b+CD146+ /W5C5/ SP), epithelial (SSEA-1+ SOX9+ / SOX9 / N-cadherin) and endothelial (SP) cell clusters. The image is reprinted from (Gargett et al. 2016) and permission for reuse provided by Rights Link Copyright clearance centre.
2. AIM AND OBJECTIVES

This study aimed to investigate early molecular alterations associated with the development of EAOC among women with ovarian endometriosis. In addition, we wanted to explore the possibilities for early detection and potential treatment strategies to reduce disease symptoms and/or inherent cancer risk among women with ovarian endometriosis, BRCA1 or BRCA2 mutations and adenomyosis.

The specific objectives of the thesis were as follows:

- To understand whether there is a molecular link between endometriosis and ovarian cancer by exploring the gene deregulations within the endometrium and endometrioma of women with ovarian endometriosis.

- To explore the role and regulation of syndecan -1 (SDC-1) and -4 (SDC-4) in Transforming growth factor-β (TGF-β) signalling on endometriotic stem/stromal cells in vitro, in order to understand interactions and involvement in the pathophysiology of endometriosis-associated cancer.

- To evaluate the mechanism of action for the selective progesterone receptor modulator, mifepristone, on BRCA1 or BRCA2 mutated ovarian stem/stromal cells in vitro, as a preventive option to reduce inherent ovarian cancer risk.

- To decipher the mechanism of action for the dopamine agonist, bromocriptine, on the endometrium of women with adenomyosis, as a prophylactic treatment option to reduce heavy menstrual bleeding.
## METHODOLOGICAL CONSIDERATIONS

### 3.1. PATIENT COHORTS AND STUDY DESIGN

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Study I</th>
<th>Study II</th>
<th>Study III</th>
<th>Study IV</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tissue biopsies of interest</strong></td>
<td>Endometrial (En)-healthy (H), Eutopic (P) and Endometrioma (Endo) biopsies</td>
<td>Endometrioma biopsies</td>
<td><em>BRCA1 or BRCA2</em> mutated ovarian punch biopsies</td>
<td>Endometrial biopsies before and after bromocriptine treatment</td>
</tr>
<tr>
<td><strong>Sample size (n)</strong></td>
<td>H-En-14, P-En-37, Endo-30</td>
<td>15</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td><strong>Inclusion criteria</strong></td>
<td>Surgically verified endometriosis (ASRM III-IV) with no indications of cancer</td>
<td>Volunteers—fertile age, regular menstruation, parity, clinically examined for the absence of hormonal disorders</td>
<td>Not applicable</td>
<td>Positive for <em>BRCA1 or BRCA2</em> mutation</td>
</tr>
<tr>
<td><strong>Exclusion criteria</strong></td>
<td>Subjects had not received any hormonal medications for at least three months before surgery. Median age &lt;45 years</td>
<td>No ovarian cancer</td>
<td>Subjects diagnosed for endometriosis by TVUS and MRI</td>
<td></td>
</tr>
<tr>
<td><strong>Median age (range) in years</strong></td>
<td>H-En ≤40; P-En &amp; Endo:33 (23-43)</td>
<td>34 (23-43)</td>
<td>42 (37-65)</td>
<td>45 (39-50)</td>
</tr>
<tr>
<td><strong>BMI (Kg/m²)</strong></td>
<td>22.3 ± 3.5</td>
<td>unknown</td>
<td>23.2 ± 2.5</td>
<td>24.4 ± 3.6</td>
</tr>
<tr>
<td><strong>Menopausal status</strong></td>
<td>Premenopausal</td>
<td>Postmenopausal-4; Premenopausal- 5</td>
<td>Premenopausal</td>
<td></td>
</tr>
<tr>
<td><strong>Menstrual cycle phase</strong></td>
<td>H-En: secretory phase; P-En-proliferative (19), secretory (17); Endo (proliferative–19, secretory–11)</td>
<td>Proliferative–4, secretory–2, others-unknown</td>
<td>Unknown</td>
<td>Proliferative phase</td>
</tr>
</tbody>
</table>
3.2. ETHICAL CONSIDERATIONS

All studies were performed in accordance with the ethical permits approved by the institutional ethical review committee at Karolinska Institutet, Sweden (Study I and II (2008/1566-31/3 and 2016/95-31/4), III (2010/661-31/1), IV (2013/2060-31/12)), University of Tartu, Estonia (Study I) and the Mayo Clinic, USA (Study IV). Study IV was approved by the Medical products agency as well as registered at clinicaltrials.gov (NCT01821001) and Eudract.ema.europa.eu (EudraCT 2013-004409-14). Informed consent was obtained from all cases and controls, prior to their inclusion in the study.

3.3. ISOLATION OF CD90⁺CD73⁺CD105⁺ STEM/STROMAL CELLS

CD90⁺CD73⁺CD105⁺ stem/stromal cells (SC⁺) were isolated from healthy volunteers (Study I), eutopic endometrium (Study I), and ectopic endometrioma (Paper I and II) from women with endometriosis, as well as 4 mm ovarian punch biopsies in women with BRCA1 or BRCA2 mutations (Paper III). We opted for the most commonly used mesenchymal markers, CD90, CD73 and CD105, suggested by the International Society for Cell Therapy (Dominici et al. 2006), the expression patterns of which have been reported to remain unaltered during prolonged culturing conditions (Jones et al. 2010; Pittenger et al. 1999). Alternatively, other markers have been suggested in the literature, such as CD146, PDGFRβ (Schwab and Gargett 2007) and SUSD2/W5C5 (Masuda et al. 2012), the expression patterns of which are altered during prolonged culturing conditions in vitro due to low oxygen tension (Tormin et al. 2011) or spontaneous differentiation (Yang et al. 2018). We restricted our analysis to sorted SC⁺ until passage 6 and adopted physiologically relevant culturing conditions such as 3D-spheroid cultures. This approach enabled us to avoid discrepancies with colony formation and multipotent differentiation capacities, reported previously on later-passaged cells (Digirolamo et al. 1999; Pittenger et al. 1999).

3.4. TARGETED PCR ARRAY AND CLUSTERING ANALYSIS

We used a targeted gene array with a customised panel of markers, previously reported for its role in premalignancy in endometriosis and/or EAOC. The list of genes is summarised in Table S1 (Paper I). This approach was preferred over whole transcriptome analysis as the expression differences observed among cancer-associated markers might be small and hence could be masked by other known genes involved in disease pathogenesis or hormone-dependent regulation.
Initially, we screened for a panel of 42 preselected genes on cultured SC+ and validated the observations with only 25 out of 42 genes on frozen tissues of both eutopic endometrium and ectopic cyst (Table S1 and marked with *). As a form of method development, we also used the above panel of genes in paraformaldehyde-fixed ectopic cyst tissues (Paper II). Furthermore, intra-patient heterogeneity based on the gene expression patterns from the above panel of genes was explored using hierarchical clustering on heatmap and principle component analysis (PCA). Using both these methods, we were able to identify samples with higher gene expression variability or molecular heterogeneity, which was later validated using functional analysis such as 3D spheroid suspension and invasion cultures.

3.5. TREATMENT DOSES

For Study II, we explored the consequences of high levels of TGF-β ligands secreted in peritoneal fluid in the context of pathogenesis of endometriosis. However, the reported TGF-β levels in the literature were ambiguous, ranging among 2 ng/ml, 250 ng/ml and 900ng/ml in women with infertility, endometriosis at stage I–II and endometriosis at stage II–IV, respectively (Pizzo et al. 2002). In contrast, only a smaller difference of approximately 10 ng/ml vs. 1 ng/ml was observed by (Oosterlynck et al. 1994) between women having endometriosis vs. control women with no benign pathology. Hence, we selected a wide range of rhTGF-β doses such as 2 ng/ml, 10 ng/ml or 250 ng/ml and an equivalent dose of transforming growth factor receptor beta-I/II (TGFRBI/II) inhibitor Ly2109761 to either activate or downregulate TGF-β signalling in vitro.

In Study III, a MIFE dose for in vitro treatment was selected based on the effect of dose dependency for proliferation and apoptosis markers. However, the optimal dose of 10 µM MIFE was equivalent to an in vivo oral dose of 200 mg MIFE, which is the (single) dose used for emergency contraceptives. Moreover, P concentration was five times greater than MIFE, in order to balance the difference between their binding affinity with PR.

In Study IV, the in vivo effects of bromocriptide on the endometrium were explored by providing 5 mg of vaginal bromocriptide treatment every day for six months to women with adenomyosis. The above dose was selected based on previous literature for reducing disease symptoms associated with hyperprolactinemia (Kletzky and Vermesh 1989).

3.6. SPHEROID CULTURES

Three-dimensional spheroid suspension and invasion cultures were used to provide a physiologically relevant condition for sorted SC+ where they exhibit their proliferation and
invasion capacity in three-dimensional space. Spheroid cultures allow cells with higher colony-forming capacity to form only multicellular spheroids during serum-starved special growth conditions; cells in the later stages of differentiation exhibit low colony-forming capacity (Kunz-Schughart et al. 1998; Lin and Chang 2008). Spheroid suspension cultures were previously used to enrich the population with cancer-initiating characteristics, known as cancer stem cells (CSC) (Dey et al. 2009; Kunz-Schughart et al. 1998). Hence, we used a specifically designed spheroid enrichment media comprising DMEM/F12 with growth factors such as FGFβ, EGF, B27, Insulin-Transferrin-selenium and allowed the SC+ to form suspension 3D spheroids by growing them in ultra-low attachment plates/flasks. The above culturing system was able to evaluate whether the aberrant gene expression within certain samples correlates with the expression profile of CSC markers. In addition, we used a 3D-spheroid invasion assay to allow SC+ from eutopic and ectopic endometrial cells to migrate within the extracellular matrix in the presence of chemotherapeutic agents such as paclitaxel to evaluate chemo-resistance in vitro (Paper I). Furthermore, we challenged endometriotic SC+ with TGF-β and/or transient gene silencing of SDC-1 or SDC-4 and evaluated for their invasive behaviour using an in vitro 3D-invasion assay, 3D spheroid formation assays and transcriptomic analysis.

3.7. TRANSCRIPTOMIC SEQUENCING AND ANALYSIS
We performed transcriptomic analysis to evaluate differentially expressed (DE) genes from invaded 3D-spheroids that were transiently silenced for genes SDC-1 or SDC-4 in combination with or without rhTGF-β (Paper III). In addition, transcriptomic profiles were assessed on endometrial tissues that were obtained before and after bromocriptine treatment in women with adenomyosis (Paper IV). Since it was required to measure transcriptome from a few thousand cells, we used a SMART-seq2 protocol for library preparation in both Studies III and IV (preparations were made in accordance with (Picelli et al. 2014)); the protocol has the sensitivity to detect signals from single cells. However, it is very selective for poly-adenylated (poly-A+) RNA; hence, information on poly-A- RNA was not detected in the analysis. Furthermore, the above protocol lacks strand specificity of mRNAs, implying that the information on copy number variability between differentially regulated genes might be lost. The Partek analysis tool (Partek Inc., CA) was used to screen for differentially expressed genes and annotate those gene expression patterns towards specific pathways involved in disease development.
4. RESULTS AND DISCUSSION

4.1. PAPER I

In this study, we hypothesised that there might be aberrant activation or silencing of genes relevant to pathways in cancer within stem/stromal cells of endometrioma, which may have a potential link with the onset/development of EAOC.

4.1.1. Eutopic and ectopic SC\(^+\) did not express ovarian CSC markers

We evaluated the gene deregulations between endometrium and endometrioma using two independent cohorts, namely, the SC\(^+\) cohort and the Tissue cohort, which involve sorted stem/stromal cells and whole tissues, respectively. We first observed that the sorted SC\(^+\) samples from both healthy and endometriosis (eutopic endometrium and ectopic endometrioma) samples in the SC\(^-\) cohort exhibited enrichment of the suggested endometrial stem/stromal markers (W5C5/SUSD2\(^+\) and MCAM/CD146\(^+\)), expressed significantly high levels of pluripotent markers (\(OCT3/4\), \(SOX2\) and \(NANOG\)) and successfully differentiated into all three mesenchymal lineages (adipocytes, osteocytes and chondrocytes) in comparison with negatively sorted SC\(^-\), hence providing substantial pieces of evidence for its multipotentiality and stem cell phenotype.

Moreover, we compared the above endometriosis and healthy control groups for expression of CSC-associated markers (ALDH1\(^+\) (Ginestier et al. 2007; Penumatsa et al. 2010; Silva et al. 2011), CD133\(^+\) (Curley et al. 2009; Kusumbe et al. 2009; Silva et al. 2011) and CD44v6\(^+\) (Gun et al. 2012; Shi et al. 2013)), which were previously characterised for their aberrant expression in ovarian cancer. As expected, CSC markers showed no significant group-wise differences between the healthy and patient sample groups, when evaluated for marker expression individually or in combination with other markers, using both real-time PCR and flow cytometry, respectively.

4.1.2. A subset of endometriomas aberrantly expressed stem- and cancer-related genes

Interestingly, one endometrioma SC\(^+\) (#36) showed an exceptionally aberrant increase in gene expression for dedifferentiation markers (\(SOX2\), \(NANOG\)), hypoxia-induced oxidative stress markers (\(HIF1\alpha\)) and higher percentage in co-expression of CD44\(^+\)CD133\(^+\) by flow cytometry; it also exhibited increased colocalization of CD44v6 and CD133 with immunofluorescent imaging analysis in comparison to all other endometrioma, eutopic as well as healthy
endometrial SC+ samples (Paper I, Fig. 3B–D). Furthermore, gene expression datasets from the targeted PCR array were analysed for intra-patient heterogeneity using hierarchical heatmap clustering and PCA. A few samples of endometrioma (such as patient nos. #36 and #24 in the SC cohort as well as E238.3 in the tissue cohort, hereafter referred to as Endo-hi) specifically showed higher molecular heterogeneity compared to other endometrioma samples (referred to as Endo-lo) such as upregulation of cancer-associated genes (E-cadherin, EPAS1 and KIT) and downregulation of tumour suppressor genes (PTEN and ARID1A which were incidentally mutated in EAOC cases (Ayhan et al. 2012; Govatati et al. 2014)). Previously, the loss of BAF250a expression (the protein encoded by ARID1A) was correlated with the early onset of EAOC (Xiao et al. 2012). Considering a lower expression pattern for ARID1A specifically in Endo-hi samples, it would be beneficial to measure the encoded BAF250a protein levels on such unique samples in the future. Moreover, Endo-hi samples from both cohorts exclusively expressed higher levels of the ER-β-to-ER-α ratio (Lazennec 2006; Pujol et al. 1998), indicating a molecular shift to compensate for the observed aberrant expression phenotype among cancer-driven genes. Incidentally, we also observed high a E-cadherin to N-cadherin ratio specifically among Endo-hi tissue (E238.3) compared to the remaining low-expression samples in the Tissue cohort.

4.1.3. An aberrantly expressed endometriotic SC+ exhibited chemotherapy resistance

We were further interested in understanding the physiological relevance of the above premalignant phenotype and correlating it with its cancer initiation capacity and chemotherapy resistance. Hence, we examined the above samples from the SC+ cohort for its invasion potential in the presence and absence of 10 µM paclitaxel treatment using a 3D-spheroid invasion system. Paclitaxel, a chemotherapeutic drug, is currently used as a first-line chemotherapy regimen for ovarian cancer (Ledermann 2018). As expected, the endometrioma SC+ group showed a significant decrease in the in vitro invasion area upon treatment with 10nM paclitaxel (1.33 µm2 vs. 2.47 µm2, P<0.05; Fig. 6) compared to no-treatment cells when cultured for an extended duration within a 3D-spheroid invasion assay. Interestingly, one of the Endo-hi samples (#36) in the paclitaxel-treated group exclusively exhibited higher in vitro invasion potential compared to other samples, indicating the possibility of the existence of cancer stem-like cells in such rare endometrioma. However, in vivo tumour formation capacity needs to be explored before further confirming the existence of CSC in such unique samples. From the above findings, we speculate there might be a very rare quiescent population with premalignant and reprogrammed characteristics, attributed to cancer initiation for samples such
as #36 (and to a lesser extent, #24), which might be clonally expanded upon activation by treatment with a high dose of chemotherapy drugs for prolonged periods of culture. Further investigation on such rare patient characteristics could potentially result in a better understanding of EAOC.

![Image of figure 6](image.png)

**Fig 6. Functional assessment of chemo sensitivity to paclitaxel treatment among high- and low-expression variability samples in an endometriosis SC cohort using in vitro 3D-spheroid invasion assay.** (A) Representative images of 3D spheroids, cultured in an extracellular matrix along with invasion media, chemoattractant MCP-1, in the presence or absence of 10 nM paclitaxel, and evaluated for its *in vitro* invasion capacity using 3D-spheroid invasion assay. B) Trend curves representing the invasion area of 3D-spheroids in the absence or presence of 10 nM paclitaxel treatment (day 0–8), measured using ImageJ software, between patient samples (i) P-EnSC and (ii) EndoSC (n=8 both). (C) Scatter plot shows the increase in invasion fold area measured at the end of 10 nM paclitaxel treatment (day 8) for individual samples within each patient subgroup, normalised against respective untreated samples (dotted line = baseline). Symbols *P*<0.05.

### 4.1.4. An aberrantly expressed endometriotic tissue had previous incidence of non-gynaecological cancers

In the Tissue cohort, the E238.3 sample was separated as an outlier (CI>95%) as it showed a unique higher variability trend among 22/25 analysed genes. Having identified some unique molecular profiles for that patient, we looked into the medical records of patients in the Tissue cohort for the risk factors associated with the disease such as stage of endometriosis, infertility, recurrent endometriosis, smoking and gynaecological/non-gynaecological comorbidities. Surprisingly, we found that patient E238.3 had been diagnosed with stage IV recurrent endometriosis at the time of surgery and had a prior history of melanoma. Though it is of a non-gynaecological cancer type, there are a few convincing epidemiological and clinical
reports on an association between endometriosis and the risk of melanoma (Kvaskoff et al. 2009; Kvaskoff et al. 2007); however, the molecular link between them is not known.

4.2. PAPER II
In this follow-up study, we intended to use the validated panel of molecular markers from Study I to identify patient samples with higher molecular heterogeneity and explore a potential treatment strategy to reverse their invasive behaviour in vitro.

4.2.1. A subgroup of endometriomas aberrantly expressed syndecans and molecules of TGF-β signalling

First, we included patient #36 from the previous study as we wanted to correlate whether the premalignant characteristics observed in Paper I could be further established with in vitro functional analysis. We performed gene expression clustering analysis on a new cohort of endometriosis samples (15 endometriotic samples, including sample #36) using 20 genes in a targeted PCR array. Two of the 15 samples (patient #36 (included from the previous study) and #23, Endo-hi) were clustered outside the ellipse in a PCA plot, implying variability with more than 95% CI. Eleven of the 15 samples (Endo-lo) had homogenous gene expression patterns. The remaining two samples (#44 and #18) showed a certain level of gene expression variability; however, it was non-significant (Fig. 1B Paper II). The two Endo-hi, when compared to the remaining samples, showed aberrant expression of molecules involved in TGF-β signalling such as TGF-β1, ESR1, CTNNB1, SNA11 and BMI1. Incidentally, also in Paper I, we observed higher mRNA levels of TGF-β1 and molecules of TGF-β signalling (BMI1 and CTNNB1) among high variability samples.

Previous studies have shown that higher TGF-β1 levels were secreted in peritoneal fluid (Oosterlynck et al. 1994; Pizzo et al. 2002; Young et al. 2014) and peritoneal and endometriotic lesions (Akl et al. 2015; Tamura et al. 1999); they were also associated with increased severity of endometriosis (Young et al. 2014; Pizzo et al. 2002; Oosterlynck et al. 1994) as well as an increase its metastatic potential in the ovary (Lamouille et al. 2014; Bierie and Moses 2006). On a similar note, heparan sulphate proteoglycan coreceptors SDC-1 and SDC-4 (Chelariu-Raicu et al. 2016) have been reported to be upregulated in endometriotic cells and their deregulation was reported in several solid tumours (Akl et al. 2015; Chen et al. 2018). In our cohort, we observed higher expression levels of SDC-4 and SDC-1 for Endo-hi compared to Endo-lo samples. Thus, by linking both these lines of thought, we explored their interactions
in the context of the pathophysiology of endometriosis and the potential risk for developing EAOC.

**4.2.2. In vitro activation of TGF-β signalling inhibited endometriotic cell growth and invasion**

We showed that activation of TGF-β signalling by treatment with 2 ng/ml rhTGF-β1 reduced the *in vitro* proliferation and invasion potential in endometriotic cell line 12Z as well as patient-derived endometriotic SC+. Alternatively, treatment with an equivalent dose (0.06 µM) of TGFRBI/II inhibitor Ly2109761 displayed increased invasion potential, thus confirming a tumour-suppressive role for TGF-β towards the pathogenesis of endometriosis (Paper II, Fig. 2). However, we did not observe any difference between the selected low (2 ng/ml) or high (250 ng/ml) rhTGF-β1 doses with respect to the key transcription factor of TGF-β signalling (*SNAI1*), protein levels of pSMAD3 as well as *in vitro* proliferation or invasion potential of endometriotic SC+ spheroids. It might be possible that the above non-significant increase upon *in vitro* rhTGF-β1 treatment might be due to the fact that endometriotic samples recruited for this study were already diagnosed with a severe stage of endometriosis (ASRM stage -3 or -4) and might therefore be prone to higher TGF-β1 levels in their peritoneal fluid and hence they were already primed to a mesenchymal phenotype via epithelial mesenchymal transition (EMT).

**4.2.3. A subset of endometriotic SC+ exhibited resistance to TGF-β induced growth inhibition**

Activation of TGF-β signalling by rhTGF-β1 on 12Z endometriotic SC+ showed significant upregulation of SDC-1 and downregulation of SDC-4 at both the mRNA and protein levels. We also observed the reversal of the above effect upon its inhibition with Ly2109761. Similar to the above response, patient-derived Endo-hi SC+ (samples #36 and #23) exclusively showed upregulation of SDC-1 compared to their respective controls, while no such difference was observed with Endo-lo samples. Likewise, Endo-hi samples also exhibited higher invasion potential upon activation of TGF-β signalling. Knowing that the aberrant expression of SDC-1 was reported in several solid tumours (Akl *et al.* 2015), we hypothesised the invasion potential of Endo-hi SC+ might be regulated by high SDC-1 expression and lead to TGF-β induced tumour suppression.
4.2.4. Transient knockdown of SDC-1 and SDC-4 reversed the premalignant characteristics during active TGF-β signalling

In line with that hypothesis, transient gene knockdown of both SDC-1 and SDC-4 reduced downstream targets of TGF-β signalling (SNAIL and pSMAD3) at both the mRNA and the protein levels. We investigated whether reducing the expression of SDC-1 and SDC-4 in the presence and the absence of active TGF-β signalling had an impact on premalignant characteristics of endometriotic SC⁺. Interestingly, the resistance towards TGF-β-induced tumour suppression, shown previously by Endo-hi SC⁺ spheroids, was reversed to a significant level only upon SDC-1 inhibition. Moreover, transcriptomic signatures from the above invaded spheroids (gene silenced for SDC-1 together with activated TGF-β signalling) showed downregulation of several cancer-associated growth signalling pathways (Paper II, Table I). Thus, we found a direct relationship between SDC-1 levels and TGF-β signalling towards regulating premalignant characteristics. Therefore, we postulate that the inhibition of high SDC-1 levels in the presence of active inherent TGF-β signalling might have an onco-protective effect on endometriomas exhibiting high molecular heterogeneity.

From the findings of Studies, I and II, we speculated on the potential mechanisms of EAOC development among women with ovarian endometriosis, in two possible steps. (A) Cells from eutopic endometrial SC⁺ may be activated due to dysregulated endometrial niche signals such as aberrant estrogen synthesis and progesterone resistance. Retrograde menstruation occurs as a consequence of uterine hyperperistalsis and other risk factors; this disperses the inherently active endometrial tissues onto the peritoneal cavity as implants/lesions. Later, aberrant estrogen signalling within these lesions stimulates SC⁺ to express high levels of markers related to epithelial mesenchymal transition (EMT) and promotes implantation of lesions on the peritoneum, ovary or other sites. (B) Upon exposure to high levels of peritoneal fluid factors or insults from chronic inflammation, ectopic endometriotic SC might develop stochastic somatic mutations within cancer driver genes; these may later cause dedifferentiation and lead to malignant transformation of cells on the ovary.

4.3. PAPER III

In this study, we focused on exploring the mechanism by which the SPRM, MIFE, acts on healthy ovaries from BRCA1 or BRCA2 mutated carriers. Currently, mastectomy and salpingo-oophorectomy are considered to be the first line of prophylactic treatment measures to reduce the incidence of breast and ovarian/fallopian cancer (Domchek et al. 2010; Kauff et al. 2008; Rebbeck et al. 2009). Previously, MIFE has been shown to inhibit cancer growth in vivo and
in vitro on ovarian cancer cell lines (Goyeneche et al. 2007). However, its molecular action on BRCA1 or BRCA2 mutated healthy ovaries still needs to be explored. Here, we hypothesised that MIFE may control cell growth on BRCA1 or BRCA2 mutated ovaries and might thereby provide an alternative treatment strategy for reducing or delaying ovarian cancer risk.

4.3.1. Heterogeneity in PR levels and their clinical impact

As we know that MIFE binds competitively with PR (Chabbert-Buffet et al. 2005), we explored whether the recruited samples possess sufficient levels of PR to have the desired drug action. We isolated the previously characterised mesenchymal stem/stromal markers CD90, CD73 and CD105 and evaluated for the expression of PR and OCT3/4 between SC⁺ and SC⁻ from BRCA1 or BRCA2 mutated ovarian cells. As we expected, SC⁺ showed significantly higher OCT3/4 expression compared to SC⁻ while PR showed a non-significant trend, indicating the relevance of this study for multipotent stem/stromal cells. Interestingly, five out of nine patients showed higher PR expression compared to the remaining samples, and the expression of the latter samples was comparatively similar to their respective sorted negative fractions SC⁻ (Fig. 1E). The above observation allowed us to question whether the higher PR levels may have a potential cancer risk. Hence, we performed a principle component analysis to correlate the heterogeneity in PR levels with their respective clinical characteristics. We categorised them into high- and low-PR expression subgroups based on the above differences and observed three distinctly separate clusters. Cluster 1 had two high-PR expressed samples, B57 and B28, marked in blue spots. Cluster 2 had one low-PR and one high-PR expressed sample, B50 and B54 respectively, marked in pink and blue spots respectively. Cluster 3 had three low-PR expression samples, B53, B45 and B26, marked in pink, and two high PR expression samples, B49 and B15, marked in blue. When analysing these cluster distributions with respect to contributing clinical factors (Figs. 7A–B), Cluster 1 comprised two high-variability PR patients who were previously reported with an incidence of breast cancer and ongoing concomitant hormonal medication, such as tamoxifen. Alternatively, Cluster 3, which has predominately more low-variability PR samples, had no previous cancer history and was not under any hormonal or concomitant medication.
Fig. 7. Correlation of PR levels with patients' clinical characteristics using principle component analysis. The graph shows (A) Clustering of BRCA1 or BRCA2 mutated samples. (B) corresponding distribution of clinical characteristics. The data was analysed using SIMCA 14 software (Sartorious Stedim Biotech) and illustrated using Prism 7 (Graphpad Inc.).

4.3.2. Anti-proliferative action for MIFE on BRCA1 or BRCA2 mutated ovaries

To study MIFE’s mechanism of action on BRCA1 or BRCA2 mutated healthy ovaries, we challenged those ovarian SC+ with increasing doses of MIFE (0.1, 1, 10, 25 and 100 µM) in vitro. We observed a dose-dependent anti-proliferative effect, with reduced expression of proliferation marker ki67 and BrdU as well as an increase in doubling time for cell growth. However, 10 µM was considered an optimal dose compared to 25 µM, as the latter does exhibit activation of BCL2 and a MAPK growth signalling pathway as well as upregulation of tumour suppressor gene TP53. Since our cohort already possesses the BRCA1 or BRCA2 mutation that induces genomic instability, the suboptimal concentration of MIFE may further disturb the growth signalling; thus, TP53 were activated to enforce regulation between survival and apoptosis machinery.

4.3.3. Combined MIFE and P treatment reduced proliferation and p21 mediated cell cycle arrest

We performed a combination treatment of MIFE with an agonist of PR and glucocorticoid receptor (GCR), namely, P or hydrocortisone (HC), in order to evaluate MIFE’s drug action with inherent P levels. In line with our hypothesis, combination treatment with P and MIFE showed reduced proliferation compared to combination treatment with MIFE and HC. Specifically, the P and MIFE combination treatment lowered the expression of proliferation (ki67 and BrdU), increased its doubling time and reducing the expression of tumour suppressor genes (TP53 and PTEN). On the other hand, BCL2 was upregulated with MIFE and P treatment. It was previously shown that BCL2 regulates pro-apoptotic or anti-apoptotic factors
based on its interaction with BAX or BCL-XL respectively (Adams and Cory 2018). Interestingly, we neither detected BAX nor cleaved caspase-3 at protein levels. In addition, the gene expression for BAX showed no difference for any of the treatments, indicating that MIFE in the presence of inherent P expression does not induce apoptosis. This also allowed us to speculate as to whether BCL2 in the absence or lower expression of TP53 may induce cell survival mechanisms, including a transient state of cell cycle arrest. As observed previously with ovarian cancer cell lines (Goyeneche et al. 2007), our data also indicated that the combination treatment of MIFE and P on BRCA1 or BRCA2 mutated ovarian cells induced cell cycle arrest at the G1/S phase, with upregulation of p21CIP1 and corresponding lower levels of CDK2 (a downstream target of p21). In addition, it presented with a higher percentage of pro-apoptotic cells. Finally, we investigated whether the drug action might cause a permanent cell cycle arrest. A kinetic proliferation assay suggested that MIFE induces only a temporary halt in growth signalling until the termination of treatment, implying the need for prolonged usage of this drug to effectively control tumour growth. The postulated mechanism of action for mifepristone from the above observations is presented in Fig. 8.

![Diagram](image)

Fig. 8. Postulated molecular mechanism of action for mifepristone among BRCA1 or BRCA2 mutation carriers. MIFE acts as a competitive agonist on either PR or GCR (or sometimes both), inducing activation of growth signalling such as MAPK-ERK or PI3K pathway which activate mTOR and increases the cellular activity, leading to active cell proliferation. Tumor suppressor gene TP53 controls the proliferative activity of cells by regulating cell cycle arrest (mediated by p21) or apoptosis (by disrupting BCL2-BAX complexes which promotes caspase 3) upon upregulation of growth signalling. This illustration is self-drawn using Adobe Illustrator, with biological arts and shapes obtained from Servier medical art, licenced by Creative Commons 4.0).
Therefore, we confirm that MIFE treatment in the presence of inherent P levels confers a potent anti-proliferative effect via inducing p21 mediated cell cycle arrest. Moreover, an optimal dose of MIFE and other SPRMs could possibly be developed as an alternative preventive strategy to retard tumour cell growth among women with BRCA1 or BRCA2 mutations.

4.4. PAPER IV

In the fourth study, we explored the mechanism of action for bromocriptine, a dopamine agonist, as a prophylactic treatment strategy for reducing disease symptoms (such as HMB, pelvic pain, etc.) associated with adenomyosis. Adenomyosis, previously known as endometriosis interna, was believed to develop when the endometrium ‘invades’ the myometrium. Adenomyosis shares several features with other gynaecological disorders (such as endometriosis and uterine fibroids), in terms of symptomology, histology and molecular alterations (Leyendecker et al. 2015; Lazzeri et al. 2014). Similar to endometriosis, adenomyosis also shows increased proliferative and invasive capacity due to increased estrogen production, progesterone resistance and impaired cytokine expression.

The pathogenesis of this disease is unknown; however, animal studies have shown that the increased prolactin levels (hyperprolactinemia) are regulated by increased levels of estrogen in the uterine cavity (Yamashita et al. 1997; Lupicka et al. 2017) and the degree of prolactin (PRL) upregulation is correlated with increased severity of the disease (Mori et al. 1991; Lupicka et al. 2017). Bromocriptine is the gold standard for the treatment of hyperprolactinemia (Kletzky and Vermesh 1989). Administration of bromocriptine vaginally to hyperprolactinaemic women lowered their PRL levels to normal, restored menstrual cyclicity and fertility (Ginsburg et al. 1992). Thus, we hypothesised that vaginal administration of bromocriptine may reduce the PRL levels as well as their accompanying disease symptoms in women with adenomyosis.

4.4.1. Bromocriptine treatment reversed tissue injury and reduce cell activity

Adenomyosis tissues were previously shown to undergo repeated tissue injury via the TIAR mechanism and healing processes, resulting in TGF-β-induced collagen deposition and fibrogenesis (Leyendecker et al. 2009; Liu et al. 2016). Our results indicated that the bromocriptine treatment inhibits fibrosis by downregulating molecules of collagen biosynthesis compared to non-treated samples. Moreover, mitochondrial genes involved in oxidative phosphorylation and active ATP production were downregulated in bromocriptine-treated samples; this was a reversal of the previous report suggesting increased oxidative phosphorylation in women with adenomyosis. Thus, we believe that bromocriptine provides a
favourable outcome by overcoming tissue injury and modulating the overall cellular activity within the endometrium of women with adenomyosis.

### 4.4.2. Patients with good response to bleeding outcomes exhibited low expression of proliferation markers

We correlated the molecular changes induced by bromocriptine treatment with the bleeding outcomes, measured using a pictorial blood loss assessment chart (PBLAC). As we expected, most of the patients in the cohort had reduced bleeding symptoms; two patients, referred to as good responders, performed exceptionally well with a PBLAC reduction score of more than 50%. We further explored the unique molecular characteristics of those two cases compared to the rest of the samples in the cohort. It was surprising to note that the treated samples did not show any significant pathway alteration between good responders and the rest of the samples. However, when we compared the untreated baseline samples, good responders showed downregulation of molecules involved in apoptosis, cell cycle, mismatch repair pathways and hedgehog signalling. Specifically, ki67 and BCL2 showed lower expression within those pathways. However, the previous report suggested that adenomyosis patients possess a higher expression of endometrial BCL2 during the proliferative phase (Jones et al. 1998). Considering that the samples obtained in the study were from the proliferative phase, we suggest the outcome of the treatment was determined based on its inherent cellular phenotype. Moreover, BCL2 negatively regulates the expression of BAX and promotes apoptosis. It was suggested that BAX expression is relatively absent among adenomyosis patients with regard to increased BCL2 expression (Huang et al. 2003). However, in our cohort, we observed a closer non-significant trend with upregulation of BAX and downregulation of ki67 for bromocriptine-treated samples, compared to the paired non-treated samples.

### 4.4.3. PRL expression correlated positively with ki67 and BAX

Previously, it was shown that engraftment of a portion of pituitary gland (which produces high levels of prolactin) within mouse uteri upregulates a 2–10-fold increase of prolactin receptor (PRL-R) and prolactin (PRL) mRNA levels and is associated with pathogenesis of adenomyosis (Yamashita et al. 1997). Correspondingly, bromocriptine was shown to reduce hyperprolactinemia (Kletzky and Vermesh 1989). Unfortunately, neither receptor showed any significant reduction upon treatment with bromocriptine compared to non-exposed tissues. Nevertheless, we found a correlation between PRL-R and PRL in relation to molecules regulating cell growth (such as ki67 and BAX). As previously observed, only the baseline treatment showed a positive correlation for ki67 and BAX with PRL. On the other hand, no
correlation was observed in relation to PRL-R either at baseline or at six months of bromocriptine treatment. To confirm whether there was a reduction in PRL secretion levels as a consequence of bromocriptine treatment, it might be worth investigating their levels in the uterine fluid of women who have undergone the above treatment. In addition, we postulate that the bromocriptine induces growth inhibition via a non-PRL-R mediated mechanism, which requires further exploration.

Therefore, we confirm that the vaginal administration of bromocriptine induced potent endometrial growth inhibition accompanied by a reversal of tissue injury. In addition, it overcame HMB, pelvic pain and other factors related to the pathogenesis of adenomyosis.
5. CONCLUSIONS

To summarise, this thesis work has shown the importance of understanding the early molecular alterations associated with malignant transformation in the ovary. This emphasises the need for early screening and establishes the possibility of development of some suitable prophylactic or preventive measures. Though the incidence of cancer is rare among individuals with endometriosis (which are usually benign), it is worth being aware of the possible warning signs and available treatment options to reduce any potential risk.

In Study I, we were able to show that the customised panel of markers was sufficient to distinguish molecular heterogeneity among endometriomas. The identified small subgroup exhibited aberrant levels of stem- and cancer-cell-related gene signatures (KIT, HIF2α, E-cadherin) dysregulated ER signalling and downregulation of key tumour suppressor genes (PTEN, ARID1A).

In Study II, functional analysis of another cohort of ovarian endometriosis enabled us to confirm that the subgroups of patients with aberrantly expressed biomarkers have anomalous behaviour/development, which can be reversed by modulating either SDC-1 or SDC-4 during active TGF-β signalling. With regard to the pathogenesis of the disease, we revealed that the presence of high levels of TGF-β may have an impact on controlling endometriotic cell growth as well as reducing their premalignant potential in vitro.

In Study III, we could evaluate the tumour-suppressive role of the SPRM, mifepristone, in controlling BRCA1 or BRCA2 mutated ovarian cell growth; this may pose an alternative treatment for reducing ovarian cancer risk as well as avoid/delay risk-reducing salpingo-oophorectomy.

In Study IV, we demonstrated the mechanism of action for bromocriptine in the first human clinical trial for the management of adenomyosis. With regard to reduced bleeding symptoms, bromocriptine provided PRL-mediated potent growth inhibition, reduced cellular activity and reversal of fibrosis demonstrating a potential role in the treatment of adenomyosis.
6. STUDY LIMITATIONS

Studies I and II

- From both the studies, 5/44 (11%) endometrioma samples showed aberrant molecular profiles for stem- and cancer-associated genes and support the potential risk of developing ovarian cancer. Considering the rare occurrence of EAOC (1–2.5%) among women with ovarian endometriosis, the above findings seems to be a bit of an overestimation compared to the actual occurrence of cancer.

- We have adopted a targeted panel of preselected genes to identify samples with higher molecular heterogeneity among women with ovarian endometriosis. This approach might have missed several other differentially regulated genes with its key role in cancer development (for instance CXCR4, which was not in our preselected panel of genes, but later identified by transcriptomic analysis on 3D-invasion spheroids in Study II).

- We have identified highly altered gene signatures among certain endometriomas in all three ovarian endometriosis cohorts, performed certain functional analyses (3D spheroids, invasion assays, chemo-resistance, etc.) and correlated their expression patterns with the clinical history of patients to speculate on their potential risk of developing EAOC. However, we may not be able to confirm whether those identified potential risk cases might really develop cancer later in life until a prospective evaluation can be done.

- In Study I, the high expression of CSC-associated makers and chemo-resistance capacity were exclusively observed in one endometrioma sample (#36) in the SC cohort. Incidentally, the same sample also showed reversal of premalignant characteristics upon inhibition of SDC-1 or SDC-4 during active TGF-β signalling (Paper I). However, the above key observation requires further validation using animal studies focussing on the existence of CSCs as well as possibilities for reducing their tumour initiating capacity in vivo.

Study III

- This study involved healthy volunteers with BRCA1 or BRCA2 mutations. However, it lacked the appropriate controls such as healthy volunteers with a non-mutated BRCA gene. Hence, we were not able to assess whether the observed cell cycle arrest was due to the impact of an error-prone DNA-damaged pathway (because of the BRCA1 or BRCA2 mutations) or the result of a mifepristone-mediated anti-proliferative effect.
We included patients with varied clinical characteristics (such as two patients with tamoxifen treatment (due to prior incidence of breast cancer), two patients with BRCA2 and the remaining five patients with BRCA1 mutations as well as differences in their menopausal status), which may have contributed to differential PR expression and exhibited variability in their anti-proliferative effect.

Study IV

The small size of the study population (only eight samples out of 18 recruited patients) were included due to occasional patient dropouts from six months’ vaginal bromocriptine treatment, poor quality of extracted RNA and stringent inclusion criteria. As a consequence, it was challenging to draw potential conclusions from the study.

There was a lot of variability with both PRL and PRL-R expression and there is no clear evidence exhibiting reduced expression of the above markers after bromocriptine treatment. Hence, further validation will be needed on the above markers at the protein level, typically using immunohistochemistry or uterine fluid to evaluate PRL levels at baseline and after six months of treatment.
7. FUTURE DIRECTIONS

For the future evaluation of early diagnostic markers towards the onset or development of EAOC, the biomarkers developed from Studies I and II should be validated. This can be achieved using archived samples from women diagnosed with ovarian endometriosis who later developed clear-cell or endometrioid subtypes of ovarian cancer and comparing the samples with a cohort of women (controls) who had ovarian endometriosis without developing ovarian cancer.

One endometrioma SC+, Endo36, which was used in both Study I and Study II, showed an aberrant molecular profile with >95% CI compared to other samples. It expressed high levels of CSC markers CD44+ CD133+ (both by flow cytometry and immunofluorescence) and dedifferentiation markers (SOX2, NANOG). Furthermore, it exhibited chemo-resistance and higher 3D-spheroid invasion potential in the presence of paclitaxel treatment (Study I) and showed resistance to TGF-β-induced growth inhibition and upregulation of SDC-1. However, inhibition of SDC-1 during active TGF-β signalling suppressed its premalignant characteristics (Study II). Evaluation of such rare samples is needed to understand the molecular mechanisms involved in the early stages of cancer development.

With respect to BRCA1 or BRCA2 mutations and ovarian cancer risk, the safety and efficacy of mifepristone after long-term treatment should be further studied and its outcomes correlated with breast and ovarian cell proliferation markers in vivo. Moreover, we should explore the molecular alterations that occur within adnexal sites (fallopian tubes, distal fimbriae, etc.) from women who underwent RRSO for preinvasive conditions such as serous tubal intraepithelial carcinoma and/or BRCA1 or BRCA2 mutation, to identify early biomarkers for high-grade ovarian cancers.

Finally, it would be interesting to investigate the possibility of using bromocriptine within an intrauterine system among women with adenomyosis, in order to evaluate its safety and efficacy for sustained relief from disease symptoms.
8. ACKNOWLEDGEMENTS

I would like to take this opportunity to thank several inspiring people who have made this journey a special and memorable one. Without all your support and encouragement, this thesis might not have been possible.

First of all, I would like to express my sincere gratitude to Karolinska Institutet (KI) and the higher education system of Sweden for providing me a world-class research environment, competent researchers with whom to interact and thought-provoking courses and literature. I truly regard this journey as an inspirational one where I have developed several skills which have not only helped me to be an independent researcher, but also a better human being.

Also, I would also like to thank the funding agencies, KI doctoral funding (KID), the Swedish Research Council, Radiumhemmet, Cancerfondon and MOMENDO Marie-Curie rise EU project for financing the research as well as my doctoral education. For grant numbers please see Paper I-IV.

My sincere thanks to the midwives and gynaecologists, both at the WHO Collaborating Centre at KI and the Ultragyn Clinic at Sofiahemmet, for your invaluable help in recruiting patients and volunteers. Most importantly, I am grateful to the women who have graciously contributed their biopsies for research.

Kristina Gemzell-Danielsson, my main supervisor. Kristina, it has been a real privilege to work with you and your constellation of wonderful people at the WHO Collaboration Centre, KI. I always think of you as a strong woman with great heart for facing challenges and handling an immense amount of stress with such a calm demeanour. I was enlightened by your leadership, your sincere dedication towards empowering women and your constant search for knowledge. I admire you for your sharp intellect, ultra-fast replies irrespective of times/days of the week and your fantastic memory of the projects, especially when so much was going around in your world of research. I am really thankful for your constant support, encouragement and trust, especially during difficult times with the manuscript and during those horrific days of thesis writing.

Lalitkumar PGL, my co-supervisor. Lalit, you are the reason why this journey started. The confidence that you instilled in me has allowed me to rediscover my talent and ability to conduct research independently. You have always provided me with challenging tasks such as writing grants soon after starting work at the lab, supervising master’s students, conducting research with freedom, etc. Though I am not sure I was ready at that time, it was one of the things that guided me to break my inhibitions and achieve whatever I have so far. Besides being a supervisor, you have been a great mentor, a well-wisher and a good family friend. I am really thankful for the care and love you have shown for my family as well as for all the valuable personal suggestions. I really missed your presence at the end but quite understand the reality of life.
Monica Nister, my second co-supervisor. Thank you for accepting me to be your student and guiding me in the world of cancer biology. Though endometriosis was a relatively new field for you as well, your readiness to learn and help me conceptually with the first study was really commendable. I enjoyed our discussions and hope our collaborations continue beyond this.

Sivamani Elumani, my first mentor. Uncle, it is my immense pleasure to mention your name in this thesis. I believe you are the one who really directed me with good thoughts and vision towards scientific research. I am deeply grateful to you for showing so much care for my career and for educating me with the dos and don’ts of scientific writing, research proposals, etc. Looking back, I can proudly state those invaluable suggestions and experiences were really useful for shaping my current research.

Merli Saare, my secret co-supervisor and dearest friend. I am truly indebted to you and thank you from the bottom of my heart for all the help you have provided, without expecting anything in return. You guided me at a crucial phase of my PhD and gave me timely suggestions when I was very stressed with manuscript rejections. Although your comments were occasionally quite challenging, they were undoubtedly the ones that changed my path for the best.

Angelique Floter-Rådestad, thank you for providing all the support, encouragement and belief that you had in me during our difficult times with the manuscript. I am very grateful to you for sharing all your knowledge and contacts in the field of gynaecological cancer. I hope our collaboration will continue beyond my PhD and hope to do much good work together.

Martin Götte and Andres Salumets, collaborators of MOMENDO project. I truly appreciate your invaluable contributions at different stages of the project, such as sharing knowledge, resources, nice co-workers as well as critical analysis on research data. Without your persistent help, it might have been difficult to achieve this. Our collaboration was so fruitful, I hope to have many more in the future.

My Lab colleagues. Nageswara Rao (Nage), you have been like a big brother to me. We have travelled this journey together since the time I joined the lab. I have truly enjoyed your presence, chats in the lab and lunch halls. You are an inspiration to me on how to deal with life’s challenges with an easy, less stressful approach. I am really thankful for your timely help with the sequencing and also for generously sharing your knowledge and experiences in the world of next-generation sequencing. Suzanna Queckborner, we had an interesting friendship that evolved over time. Thank you very much for all the nice outings, brainstorming on career paths and hot debates. You know exactly what you need in life, and most importantly, you know the path for achieving it. Keep up your good work with your PhD! And thanks in advance for being my toast madame. Dora Pavone, I am so thankful to you for helping me in times of need, both with the experiments and with proofreading of my manuscripts and thesis. I really hope you can come back to Stockholm soon and so we can work together again. Carolina Von Grothusen, I enjoyed the interesting talks and time we spent together in the lab and lunch outings. Thanks for all the useful feedbacks with the manuscript, ethical permits etc. Caroline Frisendahl, a kind-hearted person with a strong will. I am so grateful for your initiative in creating the
cover art for my thesis (please forgive me for not being able to use it in the end) as well as for proofreading my manuscripts. I hope we can work together in the future. I would also like to extend my sincere gratitude to Halima, Laura, Aditi, Jasmin, Pablo and Dora for your priceless contributions in performing experiments for my thesis. Without you, it would have been seriously difficult to complete my studies.

Catharina Karlsson, you are the backbone of our group. Thank you immensely for being a kind, caring and approachable person whom I can always go to and ask for help, suggestion and advices. Also, I would like to express my heartfelt gratitude to Anna Sandberg, Emelie Ahlin and all the administrators for taking care of my studies and employment at KBH.

Eva Broberg, I always felt the warmth of my grandmother in you (which does not mean that you are old 😊), showing lots of care and affection. We really miss your presence but happy we can meet once in a while. Thank you immensely for the recruitment of healthy controls for my studies.

Sophia Ehström, I admire your passion for research in spite of your busy schedule at Ultragyn Clinic, Sofiahemmet. I am very thankful for your help in recruiting endometriosis subjects, coordinating sample procurement and collection after surgeries, patient consent, clinical data, etc. Without your relentless help, I might have found it difficult to cross this line.

My dear colleagues at the WHO Collaboration Centre, Amanda Cleeve, Marie Klingberg Allvin, Annette Aронsson, Karin Emtell Iwarsson, Anette Daberius, Ulrika Fundin, Helena Kopp Källner, Ingrid Sääv, Niklas Envall, Susanne Sjöström, Elin Larsson, Cecilia Berger, Isabella Bizjak, Karin Andersson, Kicki Papaikonomou, former and present group members. Thank you all for the great fun that we had together during Tuesday meetings, Christmas potlucks and all the outings. I have never felt I am away from home because of your friendly, welcoming, open climate. I am also thankful to all of you for being so considerate and having all the group conversations in English.

Special thanks to Karin Emtell Iwarsson for providing a well-timed help for my wife and for taking so much care of us; Johanna Andersson and Karin Andersson for being a kind and considerate collaborators; Cecilia Berger, thanks for assisting me with endometrioma biopsy from Södersjukhuset; Helena Kopp Kalner for your timely help with providing contact with Sophiahemmet; Annette Aronsson, gratified by your kind advice during birth of my twins; Amanda Cleeve, thanks for your thoughtful help during thesis writing and Sujata Lalitkumar for being a kind family friend as well as a well-wisher whom I can always ask for advice. Really enjoyed our family meetings with Archit and hope we shall continue to meet in the future too.

People at the old FRH lab: Birgitta Byström, Yvonne Pierre, Mo, Eva Hell, Dorina, thank you for being so kind and welcoming and for taking good care of me when I came to the lab. I still cherish the morning and evening fikas we had together. Mo thank you for all the nice gifts. Dorina Ujvari, my heartfelt gratitude for being such a good friend whom I can always approach and seek advice, suggestions or help. It is good to have you around on this journey. I look back fondly on our constructive talks at lunch.
My dear lab colleagues at J9:30, Ahmed, Wei, Kai, Farasat, Jan, Cecilia, Daniel, Lulila, Magdalena, Elizabeth, Elena, Martin, Shun, Dong, Bettina, Nikolaos, Lena, Bettina, Kristiina, Yunhan, Takeo, Maryam, Francesca, Zoia, Hajar, Amanda and many others whom I have unintentionally omitted. Big thanks and hugs for being kind and welcoming colleagues. I really appreciate the lovely time we spent whenever possible. Special thanks to Cecilia, backbone of our lab, for being an approachable person whom I can always go to and ask for help. Jan and Farasat, thank you for being so open in all our discussions and exchanging several useful talks. Hats off to you both for your modesty.

My heartfelt thanks to my friends in Sweden. Kalai, Shuba, Subbu, Swetha, Deepika, Gopal, Deepi, for being a so helpful during my first days in Stockholm. Aiklan, Vishnu for always being a kind and caring neighbour. Karthik, Swetha, Deepak, Suvarna, Senthil, Sharan, Sujata, Nari, Preeti, Balaje, Supriya, Varsha, Sampath, Ekambat, Ramnath, Joshua, Prem, Siva, Viji; Uppsala friends Aravindh, Vivek, Mohan, Satish, Priya and many others whom I might have missed unintentionally. All of you have helped me in some way or other in this wonderful journey and I truly regard your company. Forgive me for being so bad at maintaining contact with you all. But I always have a special place for you all in my heart. Also, my sincere gratitude to my dearest undergraduate college friends, Sumanth, Arun, Naren, Kanimozi for constantly staying in touch with me till date.

A special thanks to Johan and Elina. I am so lucky to have your friendship and thanks a lot for constantly helping us with invaluable suggestions. The trip to Storvattnet was a memorable experience with your caring parents Inger and Paul. Johan, my fencing guru, thanks a ton for involving me into this new game and feel energised every time I come for practice. Elina, my research has developed so much based on the SIMCA that you taught me. Thanks a lot for sharing your knowledge and for being so helpful whenever needed.

My family, Amma and Appa, I finally made it!! I know how emotional this moment may be for you. Words just can’t express the sacrifices you both have made for me. You have been there for me throughout this journey, which started about 15 years ago. Thank you with all my heart for allowing me to follow my dreams and pushing me to achieve them. Amma, this work is my real dedication to you! You have told me how much you wanted to do a PhD; I hope you might experience the sweetness of it at least through me. You are the one who instilled a passion for biology from my childhood. Appa, I used to get annoyed with all the questions you would ask. But inwardly, I know that I am blessed and feel privileged to experience the immense care that a parent can show a child, to achieve the best we want for him. Chowpa, you have been a loving sister for me and always showed me so much affection. I am so sorry that I was away from our family but will always be there for you whenever its needed.

My in-laws and family, I am very much indebted to you for accepting and regarding me as an important member of your family. Uncle, my respect for you goes way beyond words. You are a true inspiration for your straight-forwardness. Without your relentless help, this thesis might not be possible. Aunty, I owe you so much for showing great care and support as well as for always trusting in my abilities. Shaki, you are the reason why
I could join hands with Sunitha. Thank you so much for regarding me and we will always be there for your family.

My loving Charlie Chaplins, Dhriti and Drish, you both have enlightened me with the experience of fatherhood. You are my cute little bundle-of-joy diversion makers. Without you, life for me and Amma would have been stereotypic. You have given us an important responsibility and we are truly indebted to you both. Thank you immensely for showering your lovely colouring skills on this thesis cover page. You may not understand now whatever I have mentioned about you, but if you happen to read this when you are old enough, you just tell yourself, “My parents were always proud of us”.

I would also extend my sincere gratitude to all the teachers of Kista international preschool (Mother goose, Kista) for taking care of our children. Especially, I am grateful for supporting us with childcare at times when we are quite late for pickups and providing replacement schools during summer. Without your help, I wouldn’t have managed to carry out research in an efficient way.

At last, my loving wife Sunitha, I am so privileged to have you as my better half. Thank you immensely!! Although I know you will not like this expression of gratitude, words just cannot explain how much you have meant to me. You have been a mother, a best friend, a companion and a mentor whom I can always approach and share my true feelings. You have showed me with the greatest care I have ever experienced but I am not sure I have shown the same to you. We joined hands somewhat earlier than we thought. You have been with me through all the tough situations and together we crossed this line!! Please forgive me for always thinking of my work; you know how much I love the work as well. I promise you that I will be bit livelier and involved with you all in future.
9. REFERENCES


Brosens I, Gordts S, and Benagiano G. Endometriosis in adolescents is a hidden, progressive and severe disease that deserves attention, not just compassion. Hum Reprod 2013; 28; 2026-2031.


Chen LL, Gao GX, Shen FX, Chen X, Gong XH, and Wu WJ. SDC4 Gene Silencing Favors Human Papillary Thyroid Carcinoma Cell Apoptosis and Inhibits Epithelial Mesenchymal Transition via Wnt/beta-Catenin Pathway. Mol Cells 2018; 41; 853-867.


Eleje GU, Eke AC, Ezebualu IU, Ikechebelu JI, Ugwu EO, and Okonkwo OO. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. *Cochrane Database Syst Rev* 2018: **8**; CD012464.


Gonzales M, de Matos LA, da Costa Gonçalves MO, Blasbalg R, Dias Junior JA, Podgaec S, Baracat EC, and Abrão MS. Patients with adenomyosis are more likely to have deep endometriosis. *Gynecological Surgery* 2012: 9; 259-264.


Kok VC, Tsai HJ, Su CF, and Lee CK. The Risks for Ovarian, Endometrial, Breast, Colorectal, and Other Cancers in Women With Newly Diagnosed Endometriosis or Adenomyosis: A Population-Based Study. Int J Gynecol Cancer 2015: 25; 968-976.


Kusumbe AP, Mali AM, and Bapat SA. CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature. *Stem Cells* 2009: **27;** 498-508.


Lin RZ and Chang HY. Recent advances in three-dimensional multicellular spheroid culture for biomedical research. *Biotechnol J* 2008: **3**; 1172-1184.


Rosen EM. BRCA1 in the DNA damage response and at telomeres. Front Genet 2013: 4; 85.


Tanase Y, Furukawa N, Kobayashi H, and Matsumoto T. Malignant Transformation from Endometriosis to Atypical Endometriosis and Finally to Endometrioid Adenocarcinoma within 10 Years. *Case Rep Oncol* 2013; **6**; 480-484.


Yamaguchi K, Mandai M, Toyokuni S, Hamanishi J, Higuchi T, Takakura K, and Fujii S. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. *Clin Cancer Res* 2008: 14; 32-40.


